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List of abbreviations
AAH: Atypical Adenomous Hyperplasia
AC: Atypical Carcinoid
ADC: Adenocarcinoma
BAC: Bronchioalveolar Carcinoma 
ChIP: Chromatin Immunoprecipitation
CIN: Chromosomal Instability
CIS: Carcinoma in Situ
CNV: Copy Number Variation
CT: Computed Tomography
DIPNECH: Diffuse Idiopathic Pulmonary Neuroendocrine Cell 
Hyperplasia
DLCO:  Diffusing Capacity
EGFR-TKI: EGFR Tyrosine Kinase Inhibitor
FEV1: Forced Expiratory Volume in 1 Second
IHC: Immunohistochemistry
IRG: Internal Reference Gene
LCC: Large Cell Carcinoma
LCNEC: Large Cell Neuroendocrine Carcinoma
MM: Mismatch
MTT: 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide, a tetrazole that can be reduced to change colors in 
living cells; used in colorimetric assays
NE: Neuroendocrine
NR: Non-Responder
PAM: Prediction Analysis of Microarrays
PET: Positron Emission Tomography
PFS: Progression Free Survival
PM: Perfect Match
R: Responder
REV: Relative Expression Value
QC: Quality Control
RR: Response Rate
SAM: Significant Analysis of Microarray
SCC: Squamous Cell Carcinoma
SCLC: Small Cell Carcinoma
SNP: Single Nucleotide Polymorphism
TC: Typical Carcinoid
TSG: Tumor Suppressor Gene
TYMS: Thymidylate Synthase

Scope of this study
NSCLC is a highly heterogeneous malignancy with a poor prognosis. Treatment 
for NSCLC is currently based on a combination of pathological staging and 
histological classification.  Recently, gene expression-based NSCLC profiling 
is proven a superior approach to stratify cancer cases with different prognosis 
and to sub-classify patients in respect of response to chemotherapy.
  The goal of the work described in this thesis is to explore the possible 
application of expression profiling in oncological practice. The proposed 
systematical scheme (Fig.1) is to distinguish NSCLC from non-cancerous lung 
using a Tumor signature; and subsequently to sub-classify NSCLC according 
to dominant molecular properties represented by a Histology signature. Next, 
the recognized cancer cases are subjected to be stratified in respect of prognosis 
according to a Survival signature. The estimated NSCLC behavior and outcome 
may direct clinicians in evaluating the aggressiveness of treatment and potential 
benefits the patient might have from that treatment. The application of expression 
profiling will be further investigated in a study in which NSCLC sensitivity 
to a chemotherapeutic agent, Pemetrexed is correlated to the expression of 
particular genes. The common feature of predicted resistant NSCLCs will be 
studied in the context of conventional histo-pathology and profiling-defined 
subgroups. The outcome of this study might indicate that molecular attributes 
of cancer cells improve insight into tumor physiology.
Fig. 1 Systematical scheme for differential diagnosis of NSCLC patients

Chapter  1 
General Introduction to Non-
small cell lung cancer
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Chapter 1
Lung cancer is a highly heterogeneous malignancy. The only hope for controlling 
this disease is to know about its etiology and pathogenesis. This study is trying 
to seek for new lung cancer diagnostic and prognostic biomarkers, and to 
understand molecular basis of chemotherapeutic sensitivity in the context of 
genome-wide expression profiling.
Epidemiology of lung cancerI. 
The incidence of lung cancer varies by age, gender, race and smoking habit. 
Lung cancer is more prevalent in males than in females worldwide. For 
example, the age-standardized rate is 109 and 20 (per 100,000) between 1993 
to 1997 in Dutch males and Dutch females respectively [1]. Worldwide, lung 
cancer is the most common cancer type in males, and the fourth in females by 
2002 [1]. In European countries, it is the second most common cancer type 
in females after 1990’s [2]. Lung cancer is the most common cause of cancer 
mortality in both males and females [3].
 Non small cell lung cancer (NSCLC) accounts for more than 80% of 
all lung neoplasms in Europe [1]. In general, squamous cell carcinoma (SCC) 
is the most frequent subtype, followed by adenocarcinoma (ADC) and large 
cell carcinoma (LCC). However, in females a different trend is seen, with ADC 
being the most prevalent. About 2 to 4% of NSCLC display mixed features, 
most commonly composed of squamous and glandular elements.
 Tobacco smoking has an established strong correlation with lung cancer 
development since the early 1960’s [4]. It is reported that by 1985 approximately 
85-90% of lung cancer cases worldwide were tobacco related [5]. The risk of 
lung cancer increases with the number of cigarettes smoked per day, the degree 
of inhalation, and the years spent smoking. Smoking increases the risk of all 
types of lung cancer, but in SCC the relationship is particularly strong [5]. 
In European countries, smoking still plays an important role in lung cancer 
development among females after the 1960’s, with the percentage of smokers 
and incidence rate of lung cancer in females reaching the highest level in history 
[6]. However, in men, the situation has changed in the past 20 years. It is noted 
that the percentage of smokers among lung cancer patients has decreased since 
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the 1960’s in men, which is probably also an explanation for the decrease in the 
incidence of squamous cell carcinoma [1]. The percentage of never smoking 
lung cancer patients is expected to decrease to 10-20% in the following years. 
The etiology of those lung cancer cases is ascribed to environmental factors 
such as population, but the exact mechanisms are unknown.
 It is noticed that the relative incidence of the various subtypes of NSCLC 
has changed over time. SCC was formerly the most frequent subtype of NSCLC. 
In the past decades, ADC appears to be the predominant type in the United 
States [7]. The higher proportion of ADC among Americans is likely related to 
the changes in smoking habits, in particular to the use of filter-tip cigarettes. It 
has been shown that 97% of smokers were using low-yield filter cigarettes by 
1992 [8]. Although filter-tip cigarettes contain less nicotine, smokers using this 
type of cigarette compensate for the lower delivery of nicotine by inhaling the 
smoke more deeply and retaining smoke longer. Consequently, the peripheral 
lung where ADC usually occurs is subjected to a higher deposition of smoke 
carcinogens [9]. In addition, low-tar filter cigarettes have a higher nitrate 
content, which induced ADC in laboratory animal models [9]. 
The higher proportion of women with ADC can also be explained by the 
smoking behavior discussed above.  
 A recently published study linked lung cancer incidence with low 
education, occupation, and low income, addressing the importance of 
socioeconomic status in lung cancer development [10].
HistologyII.  
The histological classification of lung tumors is based on light microscopic 
examination and standard histological staining techniques.  There are four 
major types of lung tumor according to the World Health Organization Lung 
Cancer Classification: squamous cell carcinoma (SCC), large cell carcinoma 
(LCC), adenocarcinoma (ADC), and small cell carcinoma (SCLC). The 
complete classification is listed in Table 1. The former three are categorized as 
non-small cell lung cancer (NSCLC). NSCLC is more common than SCLC, 
accounting for approximately 80% of all lung cancers.
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 There is a great variability in biological behavior of NSCLC and SCLC. 
These different histopathological types of lung cancer grow and spread in 
different ways and are treated differently. SCLC is a very aggressive malignancy, 
with frequent widespread metastases at early course.  It is characterized by 
properties such as contra-indication to surgery, poor prognosis, and relatively 
more sensitive to chemotherapy and radiotherapy, with a response rate more 
than 50% compared to 15% for NSCLC [11].
 SCLC traditionally was not selected for surgical removal due to its 
propensity to early metastasis. However, more recently some studies suggest 
that the combination of adjuvant chemotherapy/radiotherapy and surgery 
improved prognosis of early stage SCLC patients [12]. 
 In contrast, some of the NSCLC generally grows and spreads more 
slowly. These tumors are then less prone to develop early metastases and are 
amenable to surgical treatment at early stages. 
 Therefore, the classification as NSCLC or SCLC is of major clinical 
importance, as it significantly alters therapy guidelines. However it may be 
problematic to distinguish between these two major types of lung cancer. 
This may occur in up to 5 to 7% of cases [13]. Immunohistochemistry for 
some specific markers, such as Kit/CD117 for SCLC, might be helpful in such 
difficult diagnostic circumstances [13].
 Within the category of NSCLC, histologic subtypes are not recruited 
in routine practice because firstly until recently the histological subtypes 
of NSCLC did not alter treatment; and secondly partially due to high inter-
observer variability. Although sub-classification of NSCLC did alter little, if 
any, to the therapeutic strategy at present, the specific subtypes indicate certain 
patho-physiological and clinical patterns.
Adenocarcinoma 1. 
ADC is the most common subtype of NSCLC in the United States, and 
constitutes about 20 to 30%, with a increasing trend, of all NSCLC cases in 
Europe [7]. Being less strongly associated with smoking, adenocarcinoma is a 
predominant subtype in women in both the US and Europe [7]. 
 It is usually peripheral and arises from cells that have glandular 
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or secretory properties. Central cavitation is uncommon. On histological 
examination, ADCs often demonstrate gland formation, papillary structures, or 
mucin production. On immunohistochemical examination, the tumors usually 
stain positive for TITF1/ NKX2-1 [14]. 
 ADCs tend to metastasize to regional lymph nodes and to distant sites 
prior to the development of symptoms secondary to local disease. 
According to WHO classification 2004, lung ADC is subtyped mainly to acinar, 
papillary, and bronchioloalveolar carcinoma. However both between cases and 
within individual tumors, ADC is the most histologically heterogeneous type 
of NSCLC. The majority of ADC presents a mixture of histological features 
that probably implicate different biological behaviours [15].
 The bronchioloalveolar carcinoma (BAC) subtype of ADC arises in 
the periphery of the lung and grows along the alveolar septa. Most patients 
with BAC don’t present with a history of smoking. It may occur as early as 
the second decade of life and is associated with prior lung fibrotic disease. 
Histologically, over half of BACs are non-mucin producing tumors and have a 
slightly better prognosis compared to conventional ADC [16]. 
 Primary mucinous adenocarcinoma is a gather of any types of ADC 
with mucin secretion, including mucinous BAC, colloid ADC, and solid ADC. 
Morphologically, they resemble goblet cells. Upon immunohistochemical 
analysis, nonmucinous and mucinous BAC differ in CK20 and TITF1/ NKX2-
1 staining [16].
 Patients with adenocarcinomas may have an associated history of 
chronic lung disease, such as interstitial pneumonitis and recurrent pulmonary 
infections, and some necrotizing pulmonary diseases. In a small subset of 
ADC cases, patients present with disorders derived from endocrine and 
immune system, such as Trousseau’s syndrome. Molecules originating from 
the tumor cells such as cytokines may play a pivotal role in the pathogenesis of 
concomitant paraneoplastic complications [17].
Squamous Cell Carcinoma 2. 
With a change in smoking habits since the 1960’s, the incidence rate of SCC 
has decreased. The development of SCC is strongly associated with inhaled 
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carcinogens, as occurs in tobacco usage. 
 This type of tumor originates from epithelia lying in central bronchi. 
SCC tumors frequently present with central cavitation from necrosis and tumor 
cell exfoliation. This characteristic together with its central location makes it 
possible to detect SCC cells in sputum at an early stage.
 In well-differentiated SCC cells, keratin formation, keratin pearl 
formation, and intercellular bridging between adjacent cells are frequently 
seen.
 In a small proportion of SCC patients, increased secretion of a 
parathyroid-like hormone leads to hypercalcemia. Because of its central 
location, SCC tends to cause bronchial obstruction and atelectasis or pneumonia 
over time. 
Large cell carcinoma3.  
The histological diagnosis of LCC is largely based on exclusion of the 
other types of NSCLC, in other words, no evidence of squamous or 
glandular differentiation. Thus LCC is sometimes also referred to as poorly 
differentiated lung cancer. As a consequence, this subtype of NSCLC is highly 
heterogeneous in histopathology and clinical presentation. Furthermore, 
refined histopathological classification may lead to the diagnosis of ADC or 
SCC in cases that were previously diagnosed as LCC.
 LCC accounts for 5 ~ 10% of NSCLC [18]. It is characterized by rapid 
growth, poor differentiation, and late distant spread. Histologically, these 
tumors show large cells with large nuclei and prominent nucleoli.
 Because of the lack of well-defined classification criteria, LCC is 
usually considered as ADC with respect to therapeutic strategies [18].
Neuroendocrine carcinomas4. 
NE includes several histological subtypes: small cell lung cancer (SCLC), large 
cell neuroendocrine carcinoma (LCNEC), typical carcinoid (TC), and atypical 
carcinoid (AC). They collectively account for around 20% of lung cancer cases 
[19]. In a broader view, 10 to 20% of histologically ordinary NSCLCs can be 
identified with neuroendocrine differentiation by use of immunohistochemistry 
or electron microscopy. The percentage of NE cells ranges from 3 to 25%, in 
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admixture with non-NE components in ordinary  NSCLC [20, 21]. 
 LCNEC presents most commonly as peripheral tumors as opposed 
to TC and AC, which generally are central in location. LCNEC is a high-
grade malignant neoplasm with a relatively poor prognosis, 15 to 57% 5-year 
survival, compared to non-NE LCC [19]. Many patients with this type of 
tumor have developed distant metastases at the time of diagnosis. In contrast to 
LCNEC, TC is a low-grade and AC a medium-grade malignancy both showing 
a favorable outcome, with 5-year survival of ~87% in TC and 44 to 78% in AC 
[19]. Smoking appears to be an important factor for carcinogenesis of AC. 
 Under the microscope, these tumors present similar morphological 
appearances, such as organoid and rosette-like growth patterns, low nuclear to 
cytoplasmic ratio, a high mitotic rate, and neuro-secretory granules [22]. Since 
there is a considerable overlap in morphology and clinical presentation between 
NE tumors and other NSCLC, the routine histo-pathological examination 
is not sufficient and reliable to distinguish these tumors from others. Gene 
expression profiling might serve as a reliable mode to differentiate NE tumors 
from morphologically similar tumors, and also to differentiate within this 
category. 
 Clinically, these tumors are usually asymptomatic, if presented, the 
most common symptoms are cough, hemoptysis, and obstructive pneumonitis. 
There is no established standard therapy regimen for lung NE tumors due to 
the controversial data on survival advantage of chemotherapy from preclinical 
trials, and the low incidence of NE tumors [22].
 The fact that the majority of lung cancers are histologically 
heterogeneous has an immediate impact on the prognosis of patients since the 
histological diagnosis and pathological staging directly guide treatments. This 
phenomenon is also a main reason for variation in inter- and intra-observer 
interpretation. Heterogeneity is observed in up to 60% of lung cancer cases. 
Difference in inter-observer interpretation as to histological subclassification 
due to histological heterogeneity may occur in up to 38% of examined resections 
[23]. 
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Table 1. (2004) WHO Classification of Lung Tumors – Malignant Epithelial Tumors
I Squamous cell carcinoma
Variants:
Papillary1. 
Clear cell2. 
Small cell3. 
Basaloid4. 
II Small-cell carcinoma
Variants:
Combined small cell carcinoma1. 
III Adenocarcinoma 
Acinar1. 
Papillary 2. 
Bronchioloalveolar  carcinoma3. 
Non-mucinous (Clara/pneumocyte type II)o 
Mucinouso 
Mixed mucinous and non-mucinouso 
Solid adenocarcinoma with mucin4. 
Adenocarcinoma with mixed subtypes5. 
Variants6. 
Well-differentiated fetal adenocarcinoma•	
Mucinous (colloid) adenocarcinoma•	
Mucinous cystadenocarcinoma•	
Signet-ring adenocarcinoma•	
Clear cell adenocarcinoma•	
IV Large-cell carcinoma 
Variants: 
Large cell neuroendocrine carcinoma1. 
Combined  large cell neuroendocrine carcinoma•	
Basaloid carcinoma2. 
Lymphepithelioma-like carcinoma3. 
Clear cell carcinoma4. 
Large cell carcinoma with rhabdoid phenotype5. 
V Adenosquamous carcinoma
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VI Carcinomas with pleomorphic, sarcomatoid or sarcomatous elements
Carcinomas with spindle and/or giant cells1. 
Pleomorphic carcinoma•	
Spindle cell carcinoma•	
Giant cell carcinoma•	
Carcinosarcoma2. 
Pulmonary blastoma3. 
others4. 
VII Carcinoid tumor
Typical carcinoid 1. 
Atypical carcinoid 2. 
VIII Carcinomas of salivary-gland type
Mucoepidermoid carcinoma1. 
Adenoid cystic carcinoma2. 
Others3. 
IX Unclassified carcinoma
Grading and stagingIII. 
Prognosis of NSCLC patients much depends on the staging. Curative 
interventions – surgery, radiotherapy, chemoradiation therapy, are options 
only for patients at early stages and without the evidence of distant 
metastasis, i.e. IA to IIIA. 
 Accurate staging, which assesses the extent of local and distant 
disease, is important for properly classifying curable patients and avoiding 
invasive treatment in those presenting with disseminated cancer cells. 
 To stage a NSCLC patient, a set of physical examinations and 
laboratory tests are performed.
Complete history and physical examinationo 
CT scan of the chest and upper abdomen (including liver and o 
adrenals)
PET (Positron Emission Tomography) scano 
Bronchoscopy with transbronchial needle aspirationo 
Mediastinal staging (endoscopic ultrasound, mediastinoscopy, o 
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mediastinotomy, or thoracoscopy)
Head CT in presence of symptoms of metastatic disease or o 
evaluation appearing to be stage IIIA or IIIB
Bone scanning in presence of bone-associated symptoms, or o 
elevated calcium or alkaline phosphatase level
Complete blood cell counts o 
Liver and kidney functions tests o 
Serum electrolyteso 
Patient performance status, such as FEVo 1 and DLCO, in 
patients who are candidates for surgical resection 
 The widely accepted staging of NSCLC is based on the TNM system 
(“T” for extent of primary tumor, “N” for regional lymph node involvement, 
and “M” for metastases) (Table 2). For clinical usage, the TNM descriptor is 
sometimes integrated with the stage grouping schemes of I to III, with A or B 
subtypes (Table 3). 
 While the histological classification relies on the observed best 
differentiation of the tumor under a microscope, NSCLC is graded by their 
most poorly differentiated portion. For example, a tumor, showing obvious 
evidence of pearl formation and intercellular bridges is classified as SCC. 
Moreover, if most of the remaining tumor cells lack these characteristics, the 
tumor is graded as poorly differentiated. However, in NSCLC it is common to 
see tumor cells in a variety of differentiation stages, with some cells relatively 
well differentiated while others being very immature.
IV. Prognosis
In the past few decades, a vast effort has been put into improvement of 
the prognosis of NCSLC. However, the overall 5-year postoperative 
survival of NSCLC still stays poor due to the fact that most patients with 
NSCLC have already developed advanced disease by the time of diagnosis. 
Secondly, based on current staging techniques patients presenting with only 
micrometastases cannot be distinguished from others of limited disease. The
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Descriptors Definitions Subgroups*
T
Primary tumor
    T0
No primary tumor
    T1
Tumor	≤	3	cm,†	surrounded	by	lung	or	visceral	pleura,	not	more	
proximal	than	the	lobar	bronchus
      
  T1a
Tumor	≤	2	cm†
T1a
      
  T1b
Tumor	>	2	but	≤	3	cm†
T1b
    T2
Tumor	>	3	but	≤	7	cm†	or	tumor	with	any	of	the	following‡: 
Invades	visceral	pleura,	involves	main	bronchus	≥	2	cm	distal	to	
the	carina,	atelectasis/obstructive	pneumonia	extending	to	
hilum	but	not	involving	the	entire	lung      
  T2a
Tumor	>	3	but	≤	5	cm†
T2a
      
  T2b
Tumor	>	5	but	≤	7	cm†
T2b
    T3 Tumor	>	7	cm; T3>7
or	directly	invading	chest	wall,	diaphragm,	phrenic	nerve,	
mediastinal	pleura,	or	parietal	pericardium; T3Inv
or	tumor	in	the	main	bronchus	<	2	cm	distal	to	the	carina§;
T3Centr
or	atelectasis/obstructive	pneumonitis	of	entire	lung;
T3Centr
or	separate	tumor	nodules	in	the	same	lobe
T3Satell
    T4
Tumor	of	any	size	with	invasion	of	heart,	great	vessels,	trachea,	
recurrent	laryngeal	nerve,	esophagus,	vertebral	body,	or	carina;
T4Inv
or	separate	tumor	nodules	in	a	different	ipsilateral	lobe
T4Ipsi	Nod
N
Regional lymph nodes
    N0
No	regional	node	metastasis
    N1
Metastasis	in	ipsilateral	peribronchial	and/or	perihilar	lymph	
nodes	and	intrapulmonary	nodes,	including	involvement	by	
direct	extension
    N2
Metastasis	in	ipsilateral	mediastinal	and/or	subcarinal	lymph	
nodes
    N3
Metastasis	in	contralateral	mediastinal,	contralateral	hilar,	
ipsilateral	or	contralateral	scalene,	or	supraclavicular	lymph	
nodes
M
Distant metastasis
    M0
No	distant	metastasis
    M1a Separate	tumor	nodules	in	a	contralateral	lobe; M1aContr	Nod
or	tumor	with	pleural	nodules	or	malignant	pleural	
dissemination‖
M1aPl	Dissem
    M1b
Distant metastasis
M1b
Special situations
TX,	NX,	MX
T,	N,	or	M	status	not	able	to	be	assessed
    Tis
Focus of in situ  cancer
Tis
    T1§
Superficial	spreading	tumor	of	any	size	but	confined	to	the	wall 	
of	the	trachea	or	mainstem	bronchus
T1SS
Table 2. TNM Descriptors [24]
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Table 3. Stage Grouping
poor prognosis also results from significant inter-subtype and intra-subtype 
variability in tumor progression and response to the treatment. 
 The prognosis of NSCLC is highly associated with TNM staging of 
NSCLC. This is to a great extent a result of stage-directed treatment strategy, 
with I-IIIA stage NSCLC being subject to surgery and more advanced stages 
to chemotherapy. In general, the estimated 5-year survival rates for each stages 
are as follows [25]:
Stage IA – 68.5%o 
Stage IB – 66.6%o 
Stage IIA – 55.3%o 
Stage IIB – 49.0%o 
Stage IIIA – 35.8%o 
Stage IIIB – 35.4%o 
Stage IV - Not defined (3-year survival, 33.1%)o 
 Among patients who have developed metastasis, those with M1 
disease localized in the lung have a significant longer median survival than 
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those with metastasis in other organs. Similarly, patients with tumor cells 
metastasized to mediastinal nodal lymph nodes have a better prognosis than 
those with extra-thoracic metastases [25]. 
 The clinical outcome of NSCLC patients also varies with histological 
subtypes and tumor cell components. BAC cells are relative indolent, hence 
ADC with BAC components present relatively slower tumor growth, and 
consequently demonstrate a longer survival compared to ADC without BAC 
features [26]. In general, ADC is recognized as the type of NSCLC with the 
highest mortality. Even patients eligible for operation have a median survival 
of only 24 months from the date of surgery; and up to 71% of the survivors 
have developed recurrence within 5 years. Median survival is only 7 months 
from the date of recurrence. In contrast, patients with stage I and II SCC have 
a better 5-year survival rate in comparison to patients with ADC [25].
 Other factors which might associate with prognosis include smoking 
habits, gender, age, and the differentiation of cancer cells. The techniques and 
approaches employed to detect and histo-pathologically diagnose NSCLC 
affect the prognosis as well. 
 Although prognosis of NSCLC correlates with clinical situations 
such as pathological stage and histological subclass, the outcomes among 
patients at the same status can vary dramatically, even in early stage patients 
who had tumors surgically resected. Part of these patients could have a 
favorable 5 year postoperative survival, but others relapsed shortly after the 
initial surgery due to local or distant metastases. One explanation is that at 
the time of diagnosis and surgery those patients had already developed occult 
metastases that are undetectable by current routine examination. Therefore, 
it is vital to develop more sensitive and specific methods for detection of 
micrometastases. 
 On the other hand, expression profiling could be a more promising 
approach to predict patient outcome, and to identify patients who are unlikely 
to benefit significantly from certain therapeutic agents. A gene expression-
based stratification successfully separated early stage NSCLC patients in 
respect of risk of recurrence into different groups [27], and was applied 
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through different types of histology. The possibility of refined assessment of 
clinical outcome for NSCLC patients holds the promise to greatly improve 
prognosis not only in early stage patients. NSCLC patients at high risk of 
relapse should receive adjuvant chemotherapy after initial surgery resection, 
while patients unlikely to develop disease progression would require less 
invasive treatment to preclude treatment related mortality and morbidity.
 ChemotherapyVI. 
The main objective of treatment of advanced NSCLC where surgery is not 
possible is to palliate symptoms and to improve quality of life, and also 
presently to modestly increase overall survival. Currently, chemotherapy and 
radiotherapy are commonly used treatments for advanced NSCLC.
 Chemotherapy is the use of cytotoxic compounds to kill cancer cells or 
make them less active. Chemotherapeutic agents work by destroying rapidly 
dividing cells. Since cancer cells divide more frequently than most normal 
cells, they are particularly targeted by such drugs. Certain normal cells, such 
as those in hair follicles, the stomach epithelia, and bone marrow, divide at 
a comparable rate; therefore chemotherapy will eliminate such normal cells 
while killing cancer cells. The damage to normal cells results in the most 
common side-effects of chemotherapy, including hair loss, nausea, diarrhea, 
anemia, hemorrhage, and myelosuppression. 
 Since different chemotherapeutic agents target cells at different stages 
of cell division (Fig. 1), usually two or more agents are given at the same time 
to get the most efficient anti-rumor effect. 
Timing of Chemotherapy1. 
The timing of administration of chemotherapy differs depending on 
the specific aim. Neoadjuvant chemotherapy is given before the main 
treatment, such as surgery, to reduce the size of the tumor so as to facilitate 
the surgery more effectively. Conversely, adjuvant chemotherapy is given 
after the surgical removal of tumor, to reduce the risk of developing relapse 
due to occult cancer cells. In concomitant chemotherapy chemotherapy 
is administered at the same time as other therapies such as radiotherapy. 
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Fig. 1. Different chemotherapeutic agents target different stages of cell cycle (from 
www.drugdevelopment-technology.com)
First-line treatment represents the standard treatment (the “gold standard”) 
given when a patient is diagnosed with a particular disease or condition, such 
as advanced NSCLC. Platinum-based doublet regimen has been recommended 
as the first line chemotherapy for NSCLC, including cisplatin + paclitaxel, 
cisplatin + gemcitabine, or cisplatin + docetaxel.
 Despite the improvements in first-line chemotherapy regimens and 
the development of new drugs, over 60% of advanced patients experience 
progression and relapse. For patients with good clinical performance (PS of 0 or 
1 by ECOG score), second-line chemotherapy is recommended. Docetaxel and 
more recently Pemetrexed and EGFR-TKI (Gefitinib and Erlotinib) are mostly 
recommended after the first-line failed in stage III to IV NSCLC patients.
 Performance status (PS, ranging from 0 to 5) is a system that estimates 
a patient’s general well-being by assessing his/her daily activities. Patients 
with PS score 0 or 1 is usually regarded as having good clinical performance 
status who are asymptomatic or symptomatic but completely ambulatory.
Types of chemotherapy2. 
The majority of chemotherapeutic agents can be classified according to their 
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mechanism of action. Some agents target cells at a specific stage of cell cycle, 
such as MTX, 5-FU, bleomycin, paclitaxel, while others kill cells at any stage 
of the cell cycle. According to their site of action, chemotherapeutic agents 
can be divided into three main groups (Table 4). In general, chemotherapeutic 
agents are broad acting and display little specificity.
Table 4: Chemotherapeutic agents classification
Action site medication function
nucleotide 
synthesis 
MTX, 5-FU, Pemetrexed Thymidine synthesis
6-MP, Pemetrexed Purine synthesis
cytarabine Damage DNA; inhibit DNA 
synthesis
D N A , 
mRNA
Alkylating agents, platinum-
based
DNA cross-links
Dactinomycin, doxorubicin DNA intercalation
Bleomycin strand breakage, DNA 
intercalation
Etoposide strand breakage
steroids may trigger apoptosis
Protein Tamoxifen steroid receptor antagonist
Vinca alkaloids inhibit microtubule formation
Paclitaxel inhibit microtubule disassembly
Targeted therapy3. 
With the significant advances achieved in molecular biology, more critical 
genes in pathogenesis of NSCLC were identified that directed the development 
of a new class of therapeutic agents which manipulate specific biological 
pathways forming the basis of carcinogenesis of NSCLC. Among those agents 
include chemicals selectively working on particular genes, either established 
chemotherapeutic targets like thymidylate synthase or novel targets such as 
EGFR, as well as monoclonal antibodies against important proteins/enzymes 
from an oncogenic pathway.
 Pemetrexed, a multi-target antimetabolite, is an anti-folate 
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pyrrolopyridimine-based chemical that exerts its anti-neoplastic activity by 
disrupting folate-dependent metabolic process such as pyrimidine biosynthesis, 
essential for all cell replication (Fig. 2). It is transported into cells via the 
reduced folate carrier (SLC19A1), or membrane folate binding proteins 
including the folate receptor (FOLR1). The penta-glutamated Pemetrexed 
is the active and predominant intracellular form which has a more potent 
inhibition of its targets, and increased half-life in cancer cells. Within the cell, 
Pemetrexed prevents the formation of DNA and RNA via inhibiting at least 3 
enzymes in folate-dependent pathways: TYMS, DHFR, and GART, thereby 
blocking the proliferation of cells. Pemetrexed has been tested in advanced 
NSCLC patients from several clinical trials. The combination of Pemetrexed 
and cisplatin reached the highest response rate (RR) of 39% and 45% in two 
phase II studies, accompanying a median survival of 10.9 and 8.9 months. If 
folic acid or vitamin B12 was used as a supplement, the drug-related toxicity 
was kept at a very low level. The observations from these clinical studies 
indicate Pemetrexed as a promising agent for NSCLC treatment [28]. 
Fig. 2. Mechanism of action of Pemetrexed (from [29])
 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs), gefitinib and erlotinib, are used as first-line therapy in combination 
with other agents. In addition, EGFR-TKI showed equal activity in second 
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line compared to standard chemotherapy (Fig. 3). They have an acceptable 
tolerability profile, with an 18% RR, prolonged median survival, and a 
significant improvement in disease-related symptoms and quality of life [30]. 
Large-scale pilot studies confirmed that addition of EGFR-TKI’s to standard 
chemotherapy has not contributed to a survival increase in advanced NSCLC 
patients. Recent evidence shows, however, that maintenance treatement of 
Erlotinib was associated with a survival befefit in NSCLC patients.
 Overexpression of EGFR is observed in smoking related NSCLC and 
is associated with poor prognosis [31]. In vitro studies showed that EGFR 
tyrosine kinase inhibitors blocked the growth of human NSCLC cell lines 
via inhibition of the phosphorylation of the intracellular part of receptor and 
downstream proteins [30].
 In addition, monoclonal antibodies against VEGF as well as PKC 
inhibitors reached a median PFS of 6.7 months in recurrent NSCLC, when 
combined with chemotherapy in preclinical trials [32].
Fig. 3. Cancer drugs targeting major growth transduction pathways involved in lung 
cancer pathogenesis (from [33])
Strategy of choosing chemotherapeutic regimen4.  
The traditional development of therapeutic regimens is largely empirical. 
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Although with the appearance of new medications the treatment approach is 
more selective, it is still far away from personalized therapy targeting distinctive 
properties of cancer cells.
 The administration of Pemetrexed is dependent on the histology of 
NSCLC. Clinical trials showed that Pemetrexed is unlikely to give better 
remission rates in SCC patients compared to standard regimens, while improved 
responses were seen in ADC and LCC cases. The response to Pemetrexed might 
be dependent on differential expression of TYMS between histology types 
[34]. Accordingly, this multi-target antifolate agent is approved for treatment 
of non-SCC NSCLC where a higher RR, improved overall survival, and milder 
drug toxicity were seen [34]. 
 Similarly, targeted chemotherapy for example EGFR-TKI, holds 
promise to improve the overall survival of patients with advanced NSCLC. 
However, the response to EGFR-TKI or EGFR antibodies varies widely among 
patients with comparable tumor histopathology. Preclinical studies showed 
contradictory effects of EGFR-TKI treatment in advanced NSCLC patients 
[35]. Two large-scale studies of first-line therapy for NSCLC where the EGFR 
antibody cetuximab was given in combination with carboplatin-taxane or 
cisplatin-vinorelbine indicated that RR as well as induced PFS and overall 
survival were significantly improved among patients with EGFR mutations 
[36]. The similar results were also found in first-line treatment with EGFR-
TKI in advanced NSCLC patients [37, 38]. The lack of efficacy in the former 
studies therefore suggests that EGFR-TKI treatment may have little or no effect 
in first-line treatment in unselected patients.
 A molecular rationale is required to explain the observed low RR and 
large variation in patient response. This probably resides in differentially 
activated oncogenic pathways, not necessarily connected to histological tumor 
subtype.
Molecular prediction of response to chemotherapy 5. 
The chemosensitivity profile has been studied for decades. To date, most of 
predictive factors used in practice for chemotherapy outcome are clinical 
characteristics, for instance gender, ethnic background, and tumor stage. 
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 It has been suggested that the performance of molecular predictors may 
exceed conventional clinical parameters. The level of DNA repair enzymes was 
correlated with the efficacy of chemotherapeutic agents acting directly on the 
DNA, including alkylating agents and platinum-based compounds. Furuta et 
al., found that ERCC1, a nucleotide excision repair enzyme, is overexpressed 
in cisplatin-resistant cancer patients, indicating that the efficiency of removing 
cisplatin-induced DNA adducts by nucleotide repair enzymes plays a central 
role in cisplatin resistance [39]. Similarly, the expression level of RRM1, a 
rate-limiting enzyme in DNA synthesis, was linked to NSCLC sensitivity to 
gemcitabine, which exerts its antitumor activity by incorporation into DNA 
and subsequently arresting cell growth [40].
 Expression studies on the response of NSCLC to Pemetrexed indicated 
that TYMS and associated genes, including DHFR, GART, and MRP4, are 
important determinants for RR, and expression levels correlated negatively 
with disease-free time to progression and overall survival [41-44].
Future developments: pharmacogenomics6. 
With the identification of global patterns of gene expression, the application of 
chemotherapy is expected to be tailored to the genetic changes of individual 
tumors in order to obtain maximal efficacy and minimal toxicity.
 New technologies, such as microarrays and high throughput sequencing, 
allow for rapid identification of association between transcriptome abnormalities 
and tumor behavior to different therapeutic medications. Hsu et al., studied 
the chemosensitivity profiles of NSCLC cell lines in the NCI-60 screening 
program and discovered a panel of 45 genes as determinants for response of 
NSCLC cell lines to Pemetrexed [44]. In another study by Hanauske et al., the 
expression of targets of Pemetrexed as well as the molecules involved in in 
vivo metabolism of this drug was measured and their relationship with tumor 
reaction to Pemetrexed treatment was determined [43]. 
 The predictive role of TYMS and MRP4 for NSCLC response to 
antifolate metabolites was revealed in this study, raising the potential to apply 
expression of these proteins to guide decisions on Pemetrexed administration 
in clinical practice.
General Introduction
35
Table 5. Genomic methodologies and their application in pharmacogenomics 
(adapted from [45])
Technology Application Advantages Disadvantages
CGH Array Scanning for 
DNA deletion, 
amplification
Can analyze 
thousands 
of precisely 
mapped loci
Tedious custom 
manufacture from 
BAC clones
SNP array Detection of DNA 
polymorphisms
Detects single 
base changes, 
correlation of 
alleles with 
phenotype
PCR-based 
technologies 
cumbersome
Spotted cDNA 
microarray
Quantitate the 
expression of 
mRNAs
Inexpensive, 
ability to 
customize
Lesser density, 
infrastructure costs
Oligonucleotide 
microarray
Quantitate the 
expression of 
mRNAs
High density, 
commercial 
support, off 
shelf software
Expensive, high 
startup costs, 
inability to 
customize
Proteomics – 
2D gels
Quantitate the 
expression and 
modification of 
proteins
Discerns large 
range of protein 
molecular 
weights
Large cumbersome 
gels, large amount 
of protein, difficult 
to align spots 
across gels, only 
approximate 
molecular weights
Proteomics 
– mass 
spectrometry
Quantitate the 
expression and 
modification of 
proteins
High 
sensitivity, 
highly accurate 
molecular 
weight 
determination
High equipment 
cost, limited 
molecular weight 
range.
Tissue 
microarray
Rapid screening 
of antibodies or 
FISH probes in 
paraffin sections
Inexpensive, 
can analyze 
hundreds 
of samples, 
gives cell 
relationships
Requires paraffin 
blocks, difficult 
to score, limited 
number of sections 
from one block
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The abnormalities contributing to cancer initiation, development, and progression 
include genomic instability, such as large-scale chromosomal instability (CIN) 
and microsatellite instability (MSI); altered expression of oncogenes and tumor 
suppressor genes (TSG), like EGFR, KRAS, MYC, TP53, and RB; and resultant 
dysregulation of downstream signal pathways, including MAPK, PKC, and 
PI3K/AKT signalling; epigenetic changes - promoter hypermethylation of TSG 
and histone deacetylation, sustained angiogenesis and high rate of mitosis.
 Underlying the transformation of normal phenotypes into malignant 
phenotypes is the accumulation of multiple genetic and epigenetic alterations. 
Critical changes include oncogene activation, repression of suppressor genes, 
and loss of cell cycle- and apoptosis control. In addition, tumor development 
is characterized by genomic instability, such as chromosomal translocation. 
Previous studies showed that although some abnormalities are widely seen in 
all types of NSCLC, there are certain molecular alterations that are distinct for 
different histologic types.
Morphologic preneoplastic changesI. 
As with other epithelial malignancies, the development of NSCLC involves a 
series of progressive morphologic changes in respiratory epithelium. According 
to the histological classification of pre-invasive lung lesions by the WHO, the 
three major morphologic preneoplastic conditions include [1].
Squamous dysplasia and carcinoma in situ (CIS),1. 
Atypical adenomatous hyperplasia (AAH),2. 
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 3. 
(DIPNECH). 
 However, these lesions only account for the development of a subset of 
NSCLC. 
 The sequential premalignant lesions in central bronchi epithelium are 
well defined [2] (Fig.1),
Reserve cell hyperplasia, 1. 
Squamous metaplasia, 2. 
Low-grade dysplasia (mild dysplasia), 3. 
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High-grade dysplasia (moderate or severe dysplasia),4. 
Carcinoma in situ (CIS) 5. 
Fig. 1. Sequential histopathological and molecular changes during the pathogenesis 
of squamous cell carcinoma of the lung [3].
 Hyperplasia of the bronchial epithelium and squamous metaplasia are 
regarded reversible, whereas displasia and CIS frequently proceed to invasive 
squamous cell carcinoma. About 25% of dysplasia and 50% of CIS were found 
to progress to invasive SCC within 30 to 36 months [2]. 
 The carcinogenesis sequence for other types of NSCLC, however, has 
been poorly documented. AAH in peripheral airways, where ADC always 
arises, is supposed as the initial morphologic change in glandular neoplasm 
development [1]. In most cases, AAH arises in alveoli and are lined by cuboidal 
or columnar cells, however, the lesions are frequently found heterogeneous 
and might present multiple atypical proliferations [1]. In addition, little is 
known about the specific cell types involved in the tumorigenesis of most lung 
adenocarcinomas. If AAHs cannot regress, they progress to bronchioloalveolar 
carcinoma (BAC) and invasive peripheral ADC (Fig. 2).
 Although the precursor lesions are unknown for lung NEU, 
DIPNECH has been proposed as the premalignant change of other pulmonary 
neuroendocrine tumors, including TC and AC [1]. The hypothesis is based 
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on observations in some patients bearing carinoid tumors. In those patients, 
hyperplasia of neuroendocrine cells is always seen concurrently with carcinoid 
tumors. Thus, DIPNECH could be a preinvasive lesion, which might give rise 
to atypical or typical carcinoid. The presumed development of carcinoid tumors 
is following sequential steps: hyperplasia of airway neuroendocrine cells; 
hyperplasia invading the epithelial basement membrane; further interstitially-
extended lesion associated with fibrous tissues, also characterized as carcinoid 
tumorlet; carcinoid tumors, defined as tumorlets exceeding 5 mm in diameter.
Fig. 2. Two molecular pathways involved in the development of lung adenocarcinoma 
[3]
Cell originII. 
The classical model of carcinogenesis is a multiple step process involving 
successive accumulation of multiple genetic and epigenetic alterations, 
leading to transformation of normal epithelial cells to preneoplastic cells. 
This hypothesis is supported by extensive evidences that NSCLCs harbour 
multiple genetic and epigenetic abnormalities. In addition, preneoplastic cells 
and histologically normal bronchial epithelia present with many same types 
of abnormalities. Therefore, it is suggested that lung cancer develops from 
normal epithelial cells acquiring multiple molecular alterations.
 Variable locations of NSCLC may also indicate NSCLC originates from 
local normal epithelia cells (Fig. 3). SCC usually arises centrally from major 
bronchi where airways are lined by columnar ciliated epithelia and goblet cells. 
Considering there are no squamous cells in the normal airways, basal cells
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Fig. 3. Epithelial cells present in a normal adult lung (from www.embryology.ch) 
are presumed progenitors of preneoplastic epithelium for central located SCC 
[3]. ADC and LCC usually arise peripherally from small bronchi, bronchioles, 
or alveoli of distant airways. Clara cells, and type I and II pneumocytes are 
predominant in bronchioles and alveoli. The Clara cells and type II pneumocytes 
are responsible for the synthesis of surfactant protein A (SP-A), which is 
used as specific markers for these cell types. Type II cells are believed to be 
progenitor cells from which ADCs originate [4]. The hypothesis is based on the 
observation that some premalignant lesions and ADC cells showed phenotypes 
of type II cells. Specific markers for type II cells were present as well in almost 
all AAH, ADC using IHC staining [4].
 A fundamentally different hypothesis, cancer stem cell model, has 
become more accredited recently. This hypothesis advocates that a cancer stem 
cell or pluripotent cell is a common precursor for all types of lung tumors. 
Cancer stem cells possess stem cell like properties, including self-renewal 
and multilineage differentiation. As a consequence, tumors arisen from them 
retain the ability to undergo cell division to give rise to more cancer stem cells, 
subsequently differentiate to phenotypically diverse tumor cell population. 
Evidence for existence of cancer stem cells was reported in hematologic 
malignancies, breast cancer, and CNS tumors. Lung cancer stem cells have 
not been reported yet. However, a stem cell population which had the ability 
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of self-renewal and differentiation was isolated from the bronchioalveolar 
duct junction in the Kras mouse model [5]. Although more work is needed to 
prove the existence of lung cancer stem cells and to characterize their role in 
carcinogenesis, the heterogeneity and molecular complexity found in various 
types of lung cancer, particularly in ADC, LCC and SCLCs, indirectly support 
the cancer stem cell hypothesis.
 Two hypotheses are not necessary mutually exclusive, they might coexist 
in and/or cooperatively function for lung carcinogenesis. The majority of lung 
cancer patients are smokers whose airway epithelia are continuously exposed 
to inhaled smoke containing carcinogens and irritants and hence undergo 
chronic injury, inflammation, regeneration. In those lung cancer patients, the 
accumulation of multiple somatic mutations finally results in the transformation 
of a small portion of normal lung epithelia to cancer cells, which acquire aberrant 
over-capacity of cell proliferation, cell growth, and cell migration. Despite of 
the dominant prevalence of smokers, there is an increasing incidence of lung 
cancer among non-smokers who have no an apparent history of smoking or 
exposure to environmental carcinogens. Those patients usually have distinct 
clinical presentations compared with smoking lung cancer patients, such as 
early onset of cancer, infrequent genetic mutations, aggressive properties, and 
a high heterogeneity. Cancer stem cells are likely to be the cell origin of those 
lung cancers. They are arrested at different stages of differentiation that thus 
lead to a histological composition of multiple cell types in tumor tissue. Due 
to the low degree of differentiation and self-renew capacity, cancer stem cells 
have the potential to escape from chemotherapeutic toxicity and serve as the 
source of recurrence. 
Tumor Suppressor Gene (TSG) inactivationIII. 
TP531. 
TP53 plays a role in cell cycle control through regulating the expression of 
its downstream genes, such as CDKN1A, BAX, BCL2, and CDC2. TP53 is 
a DNA binding protein. When it binds to binding sites harboring by BAX 
and CDKN1A, it induces the expression of these genes, resulting in apoptosis 
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or G1 phase arrest. Thus, TP53 functions as a tumor suppressor gene (TSG). 
Inactivating mutations of TP53 are one of the most common genetic alterations 
in diverse human cancers, including ~ 60% of lung cancer [6]. In such cases, G1 
arrest cannot be achieved and abnormal cells proceed to S phase. The genetic 
damage is further propagated in descendant cells, which may lead to cancer.
In NSCLC, G:C to T:A mutations are the most frequent mutation of TP53, 
unlike in other solid tumors where A:T transitions are more common. And the 
G → T mutation in TP53 codon 157 is found being lung cancer specific [6]. 
In addition, TP53 mutation has been associated with tobacco exposure based 
on the finding that cigarette smoke carcinogens, benzo[a] pyrene diol epoxide 
(BPDE) adducts, are distributed more often in TP53 mutation hotspots [6].
 Although, the mutation frequency of TP53 does not show significant 
difference between smokers and non-smokers in the other study, the mutation 
pattern in different cell types is different, such as between SCC and ADC [7]. 
The different observations might due to different study populations involved 
in two studies and different codons screened. The former is conducted in the 
United States, while the later contains only Asian people, and codon 157 was 
not screened in the second study. According to Gao et al, among Asian people, 
the mutation pattern instead of transition frequency of TP53 varies between 
smokers and non-smokers and among different histology types of lung cancer 
patients. The more common G → A and T → C transitions in the TP53 gene 
were found in non-smokers, while A to G and A to C transversions are more 
frequent in SCC than in ADC [7].
 It is reported by Ikeda et al that in NSCLC patients the presence of 
TP53 mutation had an adverse impact on overall survival, at the same time, 
such patients showed significant benefits from adjuvant chemotherapy than 
those with TP53 wild type NSCLC [8].
RB2. 
RB gene was the first described TSG, and originally detected in hereditary 
retinoblastoma, hence it is named. Aberrant expression of RB gene later was 
found in other types of tumor, including lung cancer.
 RB has multiple functions relating to cell cycle progression, especially 
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in G1 to S phase transition, proliferation, differentiation, and apoptosis, thus it 
plays an important role in tumorigenesis. The disruption of the RB-Cyclin(CCN)
D1-p16 pathway has been shown to be crucial in the development of many 
solid tumors, including lung cancer. The mechanism of RB mediated tumor 
suppression is achieved by controlling the transcription of E2F-responsive 
genes.
 RB has a repressive role in regulating the transcription of E2F1 
responsive genes. The binding of RB to the binding site of E2F1 inhibits 
transcription of downstream target genes. The inhibition of RB can be reversed 
by phosporylation. Each subset of RB can be phosphorylated by different 
cyclin-CDK complexes, such as CCND1-CDK4/CDK6 and CCNE10-CDK2, 
resulting in the release of sequestrated E2F transcription factors [9]. Free E2F 
complexes drive the transcription of responsive genes including important 
protein encoding genes required for DNA synthesis, such as CCNA2, 
TK1, and DFHR. The diminishment of RB function can also be induced by 
mediated by gene mutation, homozygous/heterozygous deletion, and promoter 
hypermethylation. [9]
 RB function in NSCLC was correlated with p16/CDKN2A, p53/
TP53, and MDM2 - a reciprocal expression between RB and MDM2, p53 and 
p16 was observed in a subset of NSCLC [10, 11]. Simultaneous abnormal 
expression of RB and p16 indicated that the loss of RB function is essential 
for cell cycle proceeding initiated from p16 inactivation. In this respect, the 
tumor possessing an abnormal p16 further acquires RB mutation, consequently 
releases the inhibition to E2F1 transcription factor. If RB keeps functional, p16 
inactivation alone is unlikely to prompt tumor cell growth. On the other hand, 
the coincidence of aberration of p16-RB and p53-MDM2 in a proportion of 
NSCLC (43%) suggested a synergistic relationship between two pathways in 
carcinogenesis. The negative regulation of RB by MDM2 might mediate the 
interrelation among these proteins [10]. 
 The expression of RB was significantly decreased in MDM2-high 
tumor tissues compared with those in MDM2-low tissues. In vitro and in vivo 
studies suggested that MDM2, a ubiquitin ligase, inhibited the function of RB 
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by a ubiquitin-dependent degradation, thus promoting cell cycle progression 
from G1 to S phase. 
 Aberrant or absent expression of RB gene is more common in patients 
with neuroendocrine tumor, SCLC and LCNEC, up to 90% of patients with 
this type of tumor presented absent RB expression [10]. On the contrary, only 
25% of tumor specimens from ADC and SCC had eliminated RB expression, 
and the premaligant lesions and TC rarely exhibited abnormal RB expression. 
Different RB expression pattern is accompanied by the different RB alterations 
in subtypes of lung cancer. In SCLC and LCNEC, RB alteration might result 
from point mutations, deletion, or chromosome loss (up to 30%, 90%, and 58% 
respectively), but not promoter hypermethylation; while in NSCLC LOH and 
RB mutation is more frequent (up to 75% and 33%).
Genetic instabilityIV. 
Chr. 3p1. 
The allelic losses and homozygous deletions of 3p are detected in various types 
of cancers, including uterine cervix, renal, breast and lung cancers. In NSCLC, 
96% of patients presented LOH of at least one locus [12]. 
 Allelic loss was the most frequently detected in SCLC (85 ~ 100%), 
followed by ADC (80 ~95%). It is reported that 86% of current and former 
smokers displayed LOH in their bronchial mucosa, and 50% of the histologically 
normal specimens from smokers showed LOH, while never smokers had no 
allelic loss. One of the most frequently observed deletions is located at 3p14. 
In the region of 3p14.2, the frequency of LOH is increasing from 0 to 40%, and 
100% along with the progression of malignancy in histological changes [12]. 
Given these investigations, the allelic losses of chromosome 3p are assumed 
the earliest genetic events in lung carcinogenesis caused by exposure to smoke 
carcinogens.
 The progressive alteration was also observed in other Chr3p regions, 
such as 3p21.3. Wistuba et al. showed in SCC a significant increasing of 3p21 
allelic losses was detected with the progression of carcinogenesis, with LOH 
frequencies below 20% in normal and reversible lesions, 47 to 83% in dysplasia 
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and CIS, and 90% in invasive carcinoma [2]. 
 Moreover, a correlation between FRL, Fractional Regional Loss, and 
lung cancer development was established by Wistuba and his colleagues [2]. 
Out of 24 microsatellite markers spanning Chr3p region, FAL index was 
significantly smaller and discrete in histologically normal lung epithelium 
and mildly abnormal lesions, while in CIS and invasive carcinoma, FAL 
reached up 0.74 and 0.81. The extent of Chr3p deletion was intermediate in 
epithelial dysplasia [2]. 
Chr. 9p2. 
Like chromosome 3p, alterations of 9p have been proposed as an early event 
in NSCLC formation. Allelic loss was detected in approximately 20% of 
histologically normal tissues from SCC who had a smoking history. And the 
frequency of LOH at 9p region increases progressively along with the multi-
step SCC development [2]. One well-studied TSG, p16/CDKN2A, is mapped 
to chromosome 9p21. Its protein products function as an inhibitor of cyclin-
CDK4 complex and interact with p53-MDM2 pathway via RB, then play a role 
in cell cycle G1 control through p16-RB and p53-MDM2 networks [10].
 The loss of expression of 9p21 was found in over 80% of CIS and 
invasive SCC. By contrast, less than 20% normal and hyperplasia, around 35% 
dysplasia showed the loss of 9p21 [2]. In respect of CDKN2A, the loss of 
this gene was already seen in pre-invasive lesions of patients with CDKN2A 
negative invasive carcinoma. In patients who had retained CDKN2A expression 
in invasive carcinoma, no CDKN2A loss was observed in preinvasive lesions 
[13]. It suggests that the loss of CDKN2A expression is a critical step in early 
carcinogenesis, and is maintained during tumor progression.
 Multiple mechanisms are responsible for the loss of CDKN2A 
expression, including homozygous deletions and point mutations within the 
coding region of the CDKN2A gene and aberrant promoter hypermethylation 
[14]. Methylated CDKN2A could be detected in patient’s sputum up to 35 
months before the clinical manifestation of SCC. In addition to sputum, 
approximately 63% of corresponding bronchoalveolar lavage showed 
concordant methylation of CDKN2A. Considering that non-cancerous patients 
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rarely present methylation of CDKN2A in serum, sputum, or bronchial lavage, 
the presence of CDKN2A methylation in sputum or lavage fluid might serve as 
a highly specific marker for early diagnosis of SCC. 
Oncogene activation V. 
RAS family and downstream effectors1. 
The RAS small GTPase super family is named because of their low molecular 
weight (~20-35 kDa) and their intrinsic GTPase activity. This superfamily 
consists of more than 100 members in humans. They are ubiquitously involved 
in signal transduction and membrane trafficking. There are 6 families in 
this superfamily, RAS, RHO, ARF, RAB, RAN and RAD [15]. Oncogenic 
mutations in RAS genes are detected in nearly 30% of human cancers, with 
KRAS activating mutation frequently found in NSCLC [16].
 The RAS family contains 5 RAS – H-RAS, K-RAS, M-RAS, N-RAS, 
and R-RAS, 4 RAP – RAP1A, RAP1B, RAP2A, and RAP2B, and 2 RAL – 
RALA and RALB proteins. These RAS proteins are associated with diverse 
biological processes, including cell cycle progress, apoptosis regulation, and 
cell adhesion. Another important RAS family is RHO family, consisting of 7 
RHO, including RHOA to E, G and H, 3 RAC, including RAC1 to 3, and CDC 
42 proteins. The RHO proteins commonly act as key regulators in relation to 
cell cycle progression, actin cytoskeleton dynamics, and mobility.
 Ras protiens are membrane-bound and cycle between the GDP- and 
GTP-bound forms. In the quiescent stat, Ras exists in a RAS-GDP form. The 
sequential events, including the binding of an external ligand such as EGF 
to its receptor, phosphorylation of intracellular receptor tyrosine residue, the 
formation of adaptor complex, the interaction of adaptor complex and RAS, 
induces a change in RAS conformation and dissociation of GDP from RAS-
GDP. Subsequently, RAS binds to GTP and become active. The function 
of RAS-GTP is realized mainly via three downstream signaling pathways, 
mitogen-activated protein kinase (MAPK) cascades, signal transducer and 
activator of transcription (STAT), and phosphatidylinositol 3-kinases (PI3Ks).
 The activation of the MAPK or PI3K pathway induces the elevated 
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expression of multiple transcription factors, such as c-JUN, c-MYC, and 
c-FOS. The binding of these transcription factors to the CCND1 promoter 
results in increased transcription of genes associated with cell proliferation. 
On the other hand, RAS downstream MAPK pathway can promote cell cycle 
progression by decreasing p27 protein level through enhanced degradation. 
The high level of p27 is able to inhibit cyclin-CDK complexes and lead to cell 
cycle arrest [16]. RAS is involved in apoptosis, and cancer cell invasion via 
another downstream effector PI3K. RAS-GTP binding to a subunit of PI3K 
leads to the activation of RAC or the suppression of c-Myc. The final effect 
of PI3K pathway is the uncapping of actin filaments at plus-end or decreased 
expression of several proteins, including pro-apoptotic protein BAD, caspase 
9, and forkhead protein, then eventually induces membrane ruffling, high cell 
motility, and inhibition of apoptosis [16].
RAS mutation in NSCLC2. 
The activity of RAS is normally transient because of its intrinsic guanine 
triphosphatease (GTPase) capability which hydrolyzes the bound GTP resulting 
in the dissociation of RAS-GTP active form. Mutant variants of RAS have 
defective GTPase activities, and consequently are constitutively activated, 
resulting in the sustained activation of downstream pathways.
 KRAS point mutation was found in 48% of screened NSCLC by Gao 
and his colleagues. Since smoking is a common feature among lung cancer 
patients similar as KRAS mutation, therefore an association between smoking 
exposure and KRAS mutation it is assumed. However, in Gao’s study, no 
difference in KRAS mutation was found between smoker and non-smoker 
NSCLC patients [7]. Although no significant difference in KRAS mutation 
frequency observed, a different mutation pattern in non-smoker was detected 
by the same study, with a higher number of G → A transitions in non-smoking 
NSCLC patients. Among NSCLC types, a higher number of KRAS mutation 
was seen in SCC compared to ADC (66% vs 21%), but the difference was not 
statistically significant. Similarly, among SCC patients an A → T transversion 
was significantly more frequent in comparison with ADC [7]. These observations 
indicated that smoking status is not a reason-effect factor of KRAS mutations, 
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or not all KRAS mutations are associated with tobacco exposure.
 The relationship between KRAS mutation and tumor progression 
was studied using ADC and its corresponding premalignant lesions [17]. A 
decreasing frequency of KRAS mutations along progression of ADC was 
observed, 26.7% in AAH, 16.7% in BAC, and 10% in invasive ADC [17]. 
This result suggested that KRAS mutation must work synergistically with 
other alterations to induce NSCLC progression otherwise they would remain 
indolent.
EGFR3. 
EGFR is located on chromosome 7p12, and is a member of the ERBB family of 
tyrosine kinase receptor proteins. These family members have intrinsic tyrosine 
kinase activity, and are structurally similar in the extracelluar domain. The 
receptor exists as an inactive monomer. Upon binding to the ligands, including 
growth factors, the receptor undergoes a conformational change, which induces 
the dimerization and autophosphorylation of intracellular tyrosine domain. 
Activated EGFR subsequently results in the activation of RAS, which functions 
as a central distributor of the signal to downstream pathways important in cell 
survival and proliferation. Stimulated effector pathways include AKT signaling 
via PI3K, and MAPK signaling via RAF.
 The most common mutations in EGFR gene include: in-fram deletion 
found in exon 19, resulting in four amino acid elimination (E746-A750) in 
tyrosine kinase domain of the encoding protein; and point muation in exon 21, 
leading to leucine-arginine transversion (L858R) [18].
 These mutants confer ligand-independent activation to EGFR and 
prolong receptor kinase activity after ligand stimulation, therefore constitutively 
prompt the activity of downstream effectors. In vitro kinase activity studies, 
L858R mutant presented a ~20-fold higher catalytic efficiency than that of the 
wild-type EGFR [19]. Similarly, mouse model studies showed that expression 
of either exon 19 deletions or L858R mutant lung epithelia leads to formation 
of tumors analogous to human lung cancers [20]. 
 EGFR mutation is correlated with non-smoker, female, Asian population 
and BAC subtype [18]. In a screening for EGFR mutation in a NSCLC cohort 
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(nr.=154), mutations within exon 18 to 21 were examined using PCR assay. A 
significant difference in EGFR mutation frequency was found between female 
and male, non-smoker and former/current smoker, ADC with and without BAC 
component, and ADC with or without solid component [18].
 However, at protein level, the overexpression of EGFR had the highest 
frequency (51%) in SCC, followed by 40% in BAC, compared to 23% and 
20% in other ADC and LCC. The high EGFR protein level was correlated 
to high gene copy numbers in SCC rather than in non-SCC [21]. A similar 
overexpression of EGFR protein was also seen in BAC, but it was more 
associated to low gene copy number per cell. In contrast to SCC and BAC, low 
EGFR protein level and related balanced disomy and trisomy were observed in 
ADC [21]. 
 Tyrosine kinase inhibitors (TKI), including erlotinib, gefitinib, and 
cetuximab, can bind to EGFR and then inhibit the autophosphorylation of 
mutant EGFR, inducing apoptosis of tumor cells habouring EGFR mutations. 
Recent studies have shown that clinical response to TKIs in NSCLC patients 
is significantly associated with mutations in EGFR. As reviewed by Riely et 
al., the response rate to erlotinib or gefitinib for patients with tumors habouring 
EGFR mutations is around 75%, comparing with 10% for those whose tumors 
have wildtype EGFR [22](Fig. 4). Nevertheless, EGFR mutations are not 
equivalent in respect of clinical response to TKI therapy. Highly responsive 
NSCLC contains E746-A750 deletion in exon 19. For patients with E746-A750 
deletions, the time to progression after initial TKI treatment was 12 months, 
compared with 5 months for patients with L858R; the median survival was 34 
months for patients with E746-A750 deletions versus 8 months for those with 
L858R [23].
 Other mechanisms resulting in the activation of the EGFR pathway 
include gene amplification, amplification of a dinucleotide repeat in the 
promoter, and enhanced signaling due to heterodimerization with other 
members of the EGFR family, including HER2/HER3.
Growth stimulationVI.  
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Fig. 4. EGFR mutations and their association with sensitivity to EGFR-TKIs [22]
Apoptosis and cell cycle1. 
Expansion and progression of premalignant cells toward malignancy depend on 
the interaction of multiple biological processes, overwhelming tumorigenesis 
and disabled anti-neoplastic defenses being a common consequence.
 The most important capabilities potential tumor cells acquire during 
tumor development is to escape the physiological pathway of programmed cell 
death and to overthrow the cell cycle arrest. 
 Normal cells will undergo apoptosis under some conditions, such 
as DNA damage, oncogene activiation, and hypoxia. However, tumor cells 
are protected against apoptosis through diverse molecular pathways which 
function independently or cooperatively. The mechanism is initiated by the loss 
or inactivation of TSGs, such as P53, PTEN, and FHIT, or the overexpression 
of oncogenes, including EGFR and KRAS. The deregulation of these genes 
triggers PI3K-AKT signaling pathway, leading to a reduced apoptosis via the 
inhibition of caspases; or MAPK pathway leading to enhanced cell proliferation; 
or p53 pathway leading to impaired G1 to S phase arrest.
 In normal cells, cell cycle arrest in G1 phase is achieved by RB inhibiting 
expression of E2F responsive genes. This growth inhibition is reversed by 
the phosphorylation of RB induced by CCND1-CDK4/6. The formation of 
CCND1-CDK complexes is on the other hand inhibited by members of 
INK CDKI family, including CDKN2A, CDKN1A, and PSMD9/p27. In 
tumor cells, CCND1-CDK4/6 is activated by MAPK signaling pathway, or 
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activated indirectly as the consequence of the down-regulation of CDKN2A or 
CDKN1A. The MAPK signaling pathway is promoted by the overexpression 
of oncogenes, such as K-RAS and EGFR. In contrast, the down-regulation 
of TSGs, e.g. P53, and enhanced PI3K-AKT signaling lead to inactivation of 
CDKN1A/PSMD9. 
Angiogenesis2. 
To sustain growth and metastasize, tumors need sufficient vasculature to supply 
increased demand for nutrition and to facilitate spread of tumor cells. VEGF, 
an angiogenic factor, has a mitogenic effect on vascular endothelial cell. The 
expression of VEGF is upregulated in response to hypoxia and by activation 
of RAS. In such cases, diverse growth factors are produced by tumor cells to 
induce the formation of new blood vessels. Overexpression of VEGF is found 
in over 80% of NSCLC and premalignant lesions, indicating that VEGF plays 
a role in the early carcinogenic process [24]. 
Table 5. Frequently Involved genetic alterations in Human Lung Cancer
Oncogenes
MYC, MYCN, MYCL (deregulated expression) 
K-RAS, H-RAS, N-RAS (activating mutation) 
HER-2/neu (deregulated expression)      EGFR
Tumor-suppressor genes
3p14 (FHIT deletion) 
3p21.3 (region of the GNAI2 gene) 
3p24-25 (region of the Von Hippel Lindau gene) 
5q (FAP, MCC gene cluster) 
9p (interferon gene cluster) 
11p15, ~ 11p13 
13q14 (retinoblastoma gene, RB1) 
17p13 (TP53 gene)
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Chapter  3
High-throughput assesment 
of RNA expression by            
oligonucleotide microarray
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Gene expression has been studied for decades by various techniques. Traditional 
gene-by-gene approaches are far insufficient to understand complex cancer 
biology. New techniques with capability of profiling global gene expression 
are widely used in post-genome era.
DNA microarray technologyI. 
The high throughput microarray assay is widely used to perform genome-wide 
studies of gene expression. This technique is developed based on the principles 
utilized by Southern or Northern blotting. Instead of a few genes targeted by 
the blotting assays, the whole genome can be studied simultaneously on a 
single chip. 
 Affymetrix gene expression arrays utilize a standardized biotin-labeling 
protocol (Fig.1). To generate expression profiles by gene microarray, total 
RNAs is extracted firstly from samples of diverse resources, such as surgery 
resections, cell lines, and biopsies. Considering that RNA is highly susceptible 
to degradation, the quality of RNA has to be checked before it is processed 
further. The following sample processing includes mRNA reverse transcription, 
amplification, labeling, and chip hybridization. Taking Affymetrix expression 
assays as an example, probes on these arrays target for cRNAs. Therefore, 
the isolated mRNA must be converted to cDNA by reverse transcriptase with 
a poly-T primer. After the conversion, cDNA is transcripted by using T7-
polymerase in the presence of biotin-UTP and biotin-CTP. The biotin-labeled 
cRNA is fragmented before hybridized to Affymetrix chips. The ready-made 
arrays are washed and stained using GeneChip fluidics. Hybridization patterns 
are detected by a laser scanner reading out fluorescence emitted from cRNA 
hybridized to probes on the microarray. The intensity of emitted fluorescence 
represents the degree of expression of the mRNA or the targeted genes. The 
output intensity files are ready for further normalization and analyses. 
Affymetrix Genechip design1. 
Affymetrix Human gene expression chip is able to study over 30,000 human 
genes simultaneously. This type of array is designed in such a way that each 
gene is targeted by one or more probe-sets each comprising a set (~ 20) of 25-
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Fig 1. Affymetrix GeneChip labeling assays for eukaryotic expression microarray 
(from www.affymetrix.com)
base long DNA strands – termed probes, which are complementary sequences 
to a certain proportion of corresponding gene sequences and have a minimal 
possibility to match or cross-hybridize to the rest of the human genome.
 The principle of how microarray works is the nature chemical attraction 
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between DNA and RNA molecules, single strand DNA and RNA with 
complementary sequences can match to each other by base-pairing between 
A and U, or C and G (Fig. 2). Thus, when sample RNA/cDNA is washed over 
a microarray, matches between RNA/cDNA and their complementary probes 
are realized, and the presence of fluorescence emission reflects the expression 
of probe-targeted genes. With knowledge of predetermined location of each 
gene probe on the chip, the expression status and expression level of individual 
genes in a specific sample can be quantified by studying positional intensities 
of fluorescence.
Fig. 2. The design of Affymetrix expression GeneChip (adapted from www.affymetrix.
com)
 To evaluate and control noise such as non-specific binding of cRNA 
fragments to probes, Mismatch (MM) probes are introduced which are identical 
to Perfect Match (PM) described above with an exception for the middle (13th) 
nucleotide in the probe sequence. The real expression of gene probes can be 
estimated by using the relative expression of PM to MM. 
Microarray data analysis2.	
Gene expression data can be analyzed by a large variety of approaches. 
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There is still a lack of a standardized pipeline for processing and analyzing 
array data derived from different platforms. A few main steps, however, are 
essential and indispensable in low-level analyses for any type of microarray 
data in order to diminish noise introduced by and procedures during array 
preparation and eliminate non-biological variations. Those processes include 
data preprocessing, normalization, and filtering. 
 The algorithm developed by Affymetrix, MAS5.0 or GCOS, is widely 
used for Affymetrix expression data preprocessing. With this algorithm, the 
expression intensities are measured from both PM and MM. the final intensity 
values for each probe-set are calculated using the differences between each 
pair of PM and MM, and then combined among all probes of one probe-set by 
using one-step Turkey biweight algorithm. Afterward, all intensities on a chip 
are global scaled to make different experiments comparable. Such processed 
data are subjected to pre-filtering to remove uninformative and redundant 
information that comes from genes consistently expressed among the samples. 
The resulting data set is the basis for subsequent higher level analyses. 
 The using of mismatch expression might induce spurious estimation of 
non-specific binding. Therefore, alternative algorithms were developed in which 
only PM expression intensities were used. An example is RMA normalization 
standing for Robust Multi-array Averaging. RMA is an integrated algorithm 
comprising background adjustment, quantile normalization, and expression 
summarization by median polish. The intensities were background-corrected 
in such a way that all corrected values must be positive. The RMA algorithm 
utilized quantile normalization in which the signal value of individual probes 
was substituted by the average of all probes with the same rank of intensity 
on each chip. Finally Tukey’s median polish algorithm was used to obtain the 
estimates of expression for normalized probe intensities. GeneChip RMA (GC-
RMA) is an improved form of RMA that utilizes the sequence-specific affinities 
of the probes on chip to attain more accurate gene expression values. 
Microarray data high level analysis3.	
The most common application of microarray study is to develop gene profiles 
for relevant characteristics. It is realized by using supervised analysis, 
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with clinical information or biological phenotypes taken into account. For 
example, in a study to identify cancer related genes, gene expression from 
tumor microarrays is compared with that from normal tissues. Genes that 
show different expression patterns are supposed to be cancer initiation and 
progression associated, and are candidates for specific cancer markers. 
 The identified crude signatures can be optimized and trained to build 
refined models, which then are able to predict the presence of certain properties 
for new cases, such as the potential recurrence of disease. The power of models, 
e.g. if the model or signature reflects the biologic features rather than being 
observed by chance, usually needed to be assessed by applying the model to 
independent data sets, termed validation sets. The accuracy of prediction then 
can be evaluated using a percentage of correct classification or prediction. In 
case no independent validation sets available, “leave-one-out” cross-validation 
can be applied within the training data set. 
 Furthermore, the analysis can be performed without taking any external 
information into account, a strategy termed as unsupervised analysis. The most 
commonly application is expression profile clustering to find groups of co-
regulated genes, or samples sharing certain phenotypes. The strong point of 
unsupervised analysis is that it allows identification of underlying novel and 
unexpected patterns, for example new cancer subtypes. Such clustering is based 
on a distance metric that calculates the similarity between genes or samples. 
Similarity can be measured either by correlation coefficient or by Euclidean 
distance.
Application of gene expression profiles in oncologyII. 
Gene expression profiling has been utilized widely to address diverse biological 
characteristics, including malignant phenotypes for patient stratification. 
It has also been shown that this approach has specific power to recapitulate 
tumor histopathologic features, including identifying new cancer subtypes 
and to predict clinical outcomes using expression pattern of a set of genes. In 
addition, gene signatures have been used to predict sensitivity or resistance to 
certain chemotherapeutic agents; to identify deregulated oncogenic pathways 
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to instruct the use of targeted therapies. 
Histological feature recapitulation1. 
Gene expression profiles obtained by microarray studies to a great extent 
reflect tissue histological features. When this approach is applied to lung cancer 
research, NSCLC, SCLC, and non-cancerous tissues were distinguished from 
each other by clustering [1-4]. Within the NSCLC cluster, subgroups were 
evidently recognizable, which recapitulate major subtypes of NSCLC - ADC, 
SCC and LCC. A distinct type of NSCLC - CAR, a type of benign tumor with 
neuroendocrine feature, was distinguished from other malignant NSCLC in 
a separated cluster [1, 4]. It was positioned closely to other neuroendocrine 
tumors, SCLC and LCNEC by hierarchical clustering, but its expression 
profiles showed dissimilar patterns [1, 4]. Similarly, the heterogeneity of 
ADC was recapitulated by expression profiling. ADC shows a high degree 
of histologic complexity and is further divided into 6 subtypes according to 
the WHO classification of lung cancer. The microarray data-based clustering 
of ADC generated multiple subgroups showing diverse expression models at 
molecular level. BAC, a subtype of ADC with a distinct pathologic feature 
and relative better prognosis, presented a different profile from other types of 
ADC. This type of samples was predominant in one of few subgroups and was 
proved to be associated with good prognosis in subsequent survival analysis 
[1, 5]. The strong correlation between histologic cell types and gene profile-
based clusters implicated that cell type differentiation is the major variance 
among tumors. It also implicated that gene profiling is a promising tool to 
discern dominant oncogenic characters in highly heterogenous tumors which 
are indistinguishable by current routine histopathology. 
Clinical outcome prediction2.	
The most common way to study the association between gene expression 
profiles and patient survival is to start with predefined classes, e.g. short versus 
long survival, metastasized versus localized tumor, or relapse versus relapse-
free cases. This approach is actually a group comparison and identifies a 
signature or gene panel that is differentially expressed between two groups [6, 
7]. The genes identified in such studies are highly related with the risk of post-
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operation recurrence, and play a role in cancer cell motility and invasion. 
 Another approach that has become more and more accepted does not 
use predefined groups. By contrast, an unsupervised clustering is performed. 
It distinguishes aggressive tumors from ones with relatively good prognosis 
solely on the global gene expression patterns regardless of their histologic 
types, stages of disease, etc. [6, 8]. The gene signatures that are highly related 
with clinical outcome identified by this approach might not show extreme 
difference in expression magnitude individually. The interaction among those 
genes in a network might confer cancer cells properties favoring aggressive 
progression and early recurrence. 
New cancer subtypes identification3.	  
It has been noticed that routine histopathological classification system is insuf-
ficient to address potency of tumor progression and prognosis. Gene expres-
sion profiling is an alternative to reveal tumor features that are clinical and 
pathological outcome related. Currently, the sub-classification based on dif-
ferentiation grade and histological features of SCC and ADC is poorly corre-
lated with prognosis. Post-surgery survival varied intensively among patients 
with the same performance status or same tumor histopathology. Two profiling 
studies using DNA microarry divided SCC into two distinct groups with a sig-
nificant prognostic difference [3, 9]. Genes involved in cell proliferation, cell 
cycle transition, MAPKK cascade, and protein modification are differentially 
expressed in two subclasses. Similarly, the subdivision of ADC based on gene 
expression patterns was to a great extent correlated to clinical outcomes. ADC 
subgroups presenting favorite overall survival were defined [1, 2, 10] (Fig. 3).
Identification of deregulated oncogenic pathways4. 
The development and progression of tumor comprises the accumulation 
of multiple somatic mutations and epigenetic abnormalities that lead to 
deregulation of more than one signaling pathways important in controlling cell 
cycle progression, proliferation, and apoptosis. A strategy to study the role 
of deregulated signaling pathways in driving tumor formation is to compare 
different phenotypes in a quiescent state, which is assumed to possess inactive 
oncogenic pathways, and in an active state in which a specified pathway is
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Fig. 3. Unsupervised hierarchical clustering identified three subgroups of 
adenocarcinoma. These subgroups of ADC differed in genetic changes, tumor 
behaviors, and patient prognosis (adapted from [2]).
activated by the infection of retrovirus expressing certain gene(s). Bild et 
al. used gene expression profiling to investigate the correlation between the 
activated oncogenic pathways and tumor biology and outcome. They firstly 
identified gene signatures that reflect the activities of several well-known 
pathways, including MYC, RAS, E2F3, SRC, and β-catenin, central to 
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oncogenesis in solid cancers. The status of pathways, such as Ras pathway, 
was clearly correlated with ADC but not other NSCLC subtypes. When 
signatures for multiple key pathways were combined, they were able to 
improve the categorization of NSCLCs, breast cancers, and ovarian cancers 
in terms of prognosis and response to chemotherapeutic agents [11]. These 
observations indicated that major oncogenic pathways function differentially 
in the development of different tumor types or subtypes. And the synergic 
interaction between oncogenic pathways instead of working singularly is the 
essential determinant for cancer behavior. 
Prediction for sensitivity or resistance to clinical treatment5.	
NSCLC has a high degree histopathological heterogeneity and response 
dramatically different to therapeutic agents. Taking EGFR tyrosine kinase 
inhibitors (TKI), an approved target therapeutic agent, as an example, these 
agents only produced objective responses in 9 to 26% of advanced NSCLC 
patients in clinical trials, and about half of all treated patients developed relapse 
within 2 months of initiating therapy. Cell lines that are highly sensitive or 
highly resistant to gefitinib (EGFR-TKI) were compared to uncover 415 probe-
sets/genes associated with the sensitivity to this agent [12]. The prediction for 
gefitinib sensitivity by this gene signature on independent cohorts appeared 
to be quite promising: eleven out of twelve cell lines are correctly assigned to 
be either sensitive or resistant. Another smaller set of genes were identified as 
independent chemoresistant factors by using microarray expression profiling 
of trans-bronchial biopsies [13]. These genes include AIF1, CD74, and 
HLA-DRB1. The expression of these genes was significantly higher in non-
responders to cisplatin than that in responders, indicating correlations between 
their expression levels and tumor response to platinum-based chemotherapy.
 Given the intrinsic resistance of NSCLC to various anti-cancer agents, 
it is essential to understand the primary determinants for chemoresistance so 
to design more appropriate therapeutic regimens reaching maximal response 
within the range of tolerable drug toxicity. However, presently it is still a 
challenge to match the right drug to the right patient for oncologists. Expression 
profiling provides an opportunity to determine the activity of multiple oncogenic 
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pathways in individual patients and consequently to predict the sensitivity to 
certain therapeutic agents that specifically target given pathways. The practical 
application of this strategy makes it possible to direct individualized therapy, 
e.g. by combination of medication targeting multiple deregulated pathways, 
with the aim to improve the response rate in NSCLC chemotherapy. Moreover, 
the detection of relevant genetic heterogeneity amongst cancers open the door 
for testing combined chemotherapies in a standardized manner.
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Abstract
Current clinical therapy of non-small cell lung cancer (NSCLC) depends 
on histo-pathological classification. This approach poorly predicts clinical 
outcome for individual patients. Gene expression profiling holds promise to 
improve clinical stratification, thus paving the way for individualized therapy. 
A genome-wide gene expression analysis was performed on 91 NSCLC- and 
65 adjacent normal lung tissue samples. We defined sets of predictor genes 
with the expression profiles. The power of predictor genes was evaluated using 
independent cohorts of 96 NSCLC- and 6 normal lung samples. We identified 
a 5-gene tumor signature that aggregates the NSCLC and normal lung samples 
into the expected groups. We also identified a 75-gene histology signature, 
which classifies the samples in the major subtypes of NSCLC. Correlation 
analysis identified 17 genes showing the best association with post-surgery 
survival time. This signature stratified all patients in two risk groups with a 
significant difference in post-surgery survival time (p=5.6E-6). Compared to 
previously published prognostic signatures for NSCLC, the 17-gene signature 
performed well on the Erasmus MC- and validation cohorts. The gene signatures 
identified are promising tools for histo-pathological classification of NSCLC, 
and may improve the prediction of clinical outcome.
Introduction
Lung cancer is the most frequent cause of cancer deaths in the North America 
and Europe. In Europe alone, there were 386,300 new lung cancer cases in 2006, 
with an estimated 334,800 deaths. This accounts for 13.5% of all cancer deaths 
[1]. Based on histo-pathological presentation, lung cancer is sub-divided into 
four major histological subtypes: small cell lung cancer (SCLC), squamous cell 
carcinoma (SCC), adenocarcinoma (ADC), and large cell carcinoma (LCC). 
The latter three, collectively referred to as non-small cell lung cancer (NSCLC), 
account for almost 80% of lung cancers [2]. At present, treatment of NSCLC 
is based on histo-pathological features and staging. However, pathologically 
similar tumors with comparable stage show dramatically different response 
to the same therapy. Common features at the molecular level may be able to 
predict such outcome discrepancies among patients more reliably. For instance, 
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the efficacy of epidermal growth factor receptor (EGFR) antagonists has been 
shown to depend on expression of its target -EGFR- in the tumor [3]. Thus, 
improved classification of NSCLC is of considerable clinical interest.
 Recent advances in microarray technology enable researchers to 
recapitulate molecular properties of NSCLC at the level of individual genes 
[4-8]. However, the reproducibility of gene expression signatures to predict 
high-risk patients is rarely reported. Therefore, it is highly desirable to identify 
molecular classifiers that can reliably predict specific subgroups of high- and 
low-risk patients. This would be helpful to select the most appropriate therapy 
for individual patients.
 In this study, we performed gene expression profiling on NSCLC 
tumors and simultaneously collected normal lung tissue samples in order to 
determine histo-pathological classifier genes and high-risk index genes.
Materials and Methods
A detailed description is provided in Supplementary Methods.
Patient enrolment 
Ninety-one NSCLC patients treated at Erasmus MC were included in this 
study. Patient and tumor characteristics are listed in Table 1. All studies were 
approved by the local medical ethical committee. We used two independent 
validation sets: 6 normal lung tissues from GSE3526, and NSCLC samples 
from the Duke University cohort [12].
Pathological analysis
Tumor samples were typed by two independent routine pathological reviews, 
according to WHO guidelines [17].
RNA Isolation and gene expression profiling
Dissected tumors and adjacent normal tissue were snap-frozen in liquid 
nitrogen within two hours after surgical resection, and stored at –80 °C until 
RNA extraction. 5 μg of total RNA was processed for analysis on Affymetrix 
U133 plus 2.0 arrays using standard protocols.
Bioinformatics analyses
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Table 1. Clinical characteristics of NSCLC cohort.
Standard QC methods were used to control the overall quality of arrays. 
The final intensity value of probe sets was summarized as the deviation to 
the geometric mean of that probe set among all arrays. Uninformative probe 
sets were eliminated and the remaining probe sets were used for subsequent 
analyses.
Class comparison
Two-group comparisons were performed by Significance Analysis of 
Microarrays [18]. This supervised analysis correlates gene expression with a 
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clinical variable based on a score calculated using the change in expression and 
the standard deviation across all samples.
Class prediction
All primary signatures were optimized to identify subgroups of genes that 
maintain the capacity in distinguishing different groups maximally [9]. The 
performance of optimized signatures was validated by “leave-one-out” cross 
validation within the training set firstly, then with the validation set [10]. 
Hierarchical clustering was performed using the Spotfire Decision Site.
Survival analysis
We used a step-wise approach based on gene expression profiles to classify 
NSCLC with respect to prognostic outcome. Firstly, the Wald test in the Cox 
proportional hazards model was used to identify prognostic genes most likely 
associated with overall survival [11]. Candidate genes were selected based on 
p-values (< 0.001) computed from 1000 random permutations. The resulting 
candidate survival genes were subjected to a supervised analysis [12], which 
comprises computation of principal components, Cox proportional hazards 
regression analysis using these principal components, and finally prognostic 
predictor calculation by fitting the predictive prognosis model derived from 
the Cox regression. The predictive value of the prognosis model was evalu-
ated by “leave-one-out” cross-validation [12, 13]. The prognostic value of the 
predictor relative to clinical variables, such as age, tumor cell content (%), 
tumor size, pack years, Forced Expiratory Volume 1, gender, histology, and 
tumor grade was tested by the Wald test (Supplementary Table 7). The correla-
tion between the survival signature and clinical parameters is summarized in 
Supplementary Table 6.
Other NSCLC prognostic classifiers
The 20- and 6-probe set predictors were developed by Lee et al [14]. Additional 
survival related signatures include one derived from Affymetrix U133A 
chips [15], one from Affymetrix HuGeneFL chips [16, 17], two from other 
types of oligonucleotide arrays [18, 19], and one from RT-PCR assays [20] 
(Supplementary Table 8).
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Results
Study design
Tumors (n=91) and unaffected lung tissue samples (n=65) were collected from 
NSCLC patients undergoing lung resection at Erasmus MC. Tissue specimens 
were snap frozen in liquid nitrogen and stored at –80 °C until further processing. 
Clinical parameters of the patients are summarized in Table 1. Paraffin sections 
of the tumors were scored by routine pathology and an independent pathologist 
(MdB). We isolated RNA from 25 μm cryostat sections of the snap-frozen 
specimens and used this for labelling and hybridisation to Affymetrix U133 
2.0 plus arrays. Tumor cell content was determined from 10 μm sections taken 
at the start and end of cryostat cutting. The samples were divided into training 
and validation sets (Table 1; see Supplementary Materials for criteria). 
Signature genes distinguish NSCLC from normal lung tissue
By unsupervised Pearson’s correlation analysis, tumor samples were clearly 
separated from healthy lung samples (Fig. 1). We therefore first sought to derive 
a minimized signature gene set that could distinguish tumors from healthy 
lung tissue. To this end, we compared gene expression profiles from 44 tumors 
with that from 36 healthy lung tissues. By supervised analysis, we identified 
187 genes that were differentially expressed in the NSCLC samples (Fig. 2A 
and Supplementary Table 1). Using Prediction Analysis of Microarrays we 
found that a 5-gene signature distinguished healthy tissue from NSCLC with 
an accuracy of 98%, (Fig. 2B and Supplementary Table 2). Two tumor and 
three non-cancerous lung samples were incorrectly classified by the 5-gene 
signature. Of these, one presented with an uncertain histological diagnosis, 
and two were from patients with multiple primary tumors. Weconclude that 
the 5-gene signature accurately distinguishes NSCLC from healthy lung tissue, 
regardless of NSCLC subtype.
NSCLC are sub-classified by histology signature genes
As NSCLC are tumors with a high degree of heterogeneity, genes characterizing 
histological features were identified using strictly selected tumor samples. 
Firstly, the histological diagnosis had to be consistent between the two 
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independent pathology reviews, resulting in forty-nine cases left. Secondly, 
the samples should not display apparent tumor cell heterogeneity. Thirdly, the 
content of cancer cells should be above 60%. This super-training set consisted 
twenty-three cases. We compared the gene expression profiles of each NSCLC 
subtype to those of the remaining samples, and identified 518 genes representing 
the three major subtypes of NSCLC: ADC, SCC, and LCC (Supplementary 
Table 3). Using “leave-one-out” cross validation, we found that the percentage 
of correct classification by Prediction Analysis of Microarrays was 96% (22 
out of 23) in the training samples (Fig. 3A). When this signature was applied 
to classify the validation samples, we found that the three carcinoid (CAR) 
samples, which were not involved in deriving the signature, and one LCC 
sample were separated from the other tumors, thus representing a unique group 
(Fig. 3B). We note that the LCC sample in this group was classified as CAR by 
the second pathology review. The optimized signature gene set consisted of 75 
genes (Supplementary Table 4). This optimized signature classified the training 
samples with 100% accuracy (Fig. 3A). This signature was applied to predict the 
histology subtype of the samples with conflicting pathology diagnoses (n=18). 
Of these 18 samples, one had an ambiguous diagnosis due to unsatisfactory 
histology, and three had a tumor cell content of less than 20%. We note that 
over 60% (n=11) of these 18 samples presented with apparent tumor cell type 
heterogeneity. With three exceptions, the ambiguously classified LCCs (n=11) 
were classified as ADC or SCC, and this was consistent with the primary 
diagnosis (Fig. 4A). We conclude that the 75-gene histology signature may 
aid in assigning the correct histological classification in ambiguous NSCLC 
cases.
Survival risk prediction
Starting with the 11,515 probe sets remaining from the data filtering process, 
we used the Wald test from the Cox proportional hazards model to identify the 
genes that were best correlated with survival time. The principal components 
computed from the expression of these genes were subjected to Cox propor-
tional hazard regression analysis, and built up a model for predicting a prog-
nostic probability for each NSCLC case. The predictive value of the prognosis 
80
Chapter 4
Figure 1. Correlation view of 156 samples from patients with NSCLC. 
Pairwise correlations between any two samples are displayed, based on 4791 
informative probe sets. The colors of the cells represent Pearson’s correlation 
coefficient values, with deeper red indicating higher positive and deeper blue lower 
negative correlations. The red diagonal line displays the self-to-self comparison of 
each sample. Histological classification of the samples is depicted along the diagonal; 
the key to the color code is shown at the bottom. Histo-path_1 & Histo-path_2: initial 
and second histo-pathological review.
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Figure 2. Hierarchical clustering distinguishes tumors from healthy lung tissue.
A. Two-dimensional hierarchical clustering of 80 training samples, including tumors 
and healthy lung samples, was performed with 187 genes. The relative expression to 
the overall mean for each probe set (rows) in each sample (columns) is indicated by 
a color code. B. Hierarchical clustering of 156 tissue samples with 5 genes yields 2 
groups, tumor and normal lung
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model was evaluated by “leave-one-out” cross-validation. This resulted in an 
optimized model consisting of 17 genes. A risk percentile cut-off of 60% was 
used to define two risk groups, which were distinguished at significance p-
value = 5.6E-6 by log-rank test. A Kaplan-Meier curve of overall survival from 
these two risk groups is shown (Fig. 5A). 
 The association between the prognosis profile and clinical parameters 
was studied. The prognosis profile was significantly associated with age 
(p<0.023), pack years (p<0.014), gender (p<0.012) and Forced Expiratory 
Volume 1 (p<0.009), but not with tumor stage, cell content, histology and 
size (Supplementary Table 6). We performed multivariate proportional hazard 
regression analysis to evaluate the predictive value of the prognostic predictor 
for patient outcome in comparison with other clinical parameters. No evidence 
of relation was found between relative hazard ratio and age, gender, pack years, 
tumor cell content, Forced Expiratory Volume 1, tumor histology and tumor 
size. Supplementary Table 7 shows the Wald statistics and significance for 
each variable tested. Tumor stage and the 17-gene prognostic predictor were 
significantly related to the hazard of death. However, the prognostic predictor 
presented the highest importance: 21.68 compared to 3.80 from tumor stage. 
Moreover, the relative hazard ratio predicted by the prognostic predictor was 
2.47 (95% confidence interval, 1.69 to 3.60, p<1.5E-06), the highest among all 
tested risks (Table 2). 
Table 2. Multivariable proportional hazard analysis of the risk of death
 Similarly, inclusion of the prognostic predictor into the predictive 
model improved model performance to 19.5, in terms of -2 log likelihood, with 
a p-value of 9.8E-06, compared to 24.3 and p-value 2.0E-03 without it. Thus, 
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Figure 3.  Clustering analysis of NSCLC tumors with the 518 probe set histology 
signature
A. agglomerative hierarchical clustering of 23 NSCLC samples using the 518 probe 
set histology signature. The relative expression to the overall mean for each probe set 
(rows) in each sample (columns) is indicated by a color code. Correlation between the 
samples is depicted by the dendrogram. Histo-pathological diagnosis and predictions 
of histology subtype by Prediction Analysis of Microarrays, using the 518 and 75 probe 
set signatures, are shown by colored blocks. B. correlation dendrogram generated by 
agglomerative hierarchical clustering of all 91 Erasmus MC NSCLC samples using 
the 518 probe set signature. Histo-pathological diagnosis of the initial and second 
review, and prediction of histology subtype by Prediction Analysis of Microarrays 
using the 518 probe set signature, are shown by colored blocks.
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multivariate proportional hazard analysis indicates that the 17-gene signature 
is the strongest survival predictor.
Validation of gene signatures
We studied the expression patterns of all signatures in two independent sets of 
microarray data collected in the United States, consisting of the NSCLC cohort 
from Duke University (n = 96) [21], and 6 normal lung specimens (GSE3526). 
These were chosen because 1) they were also analyzed on the Affymetrix 
U133 plus 2.0 arrays, and 2) the original .CEL files were available (i.e. raw 
rather than pre-normalized data). The 5-gene tumor signature performed on the 
validation set with an accuracy of 97%: 93 out of 96 NSCLC were correctly 
classified as ‘tumor’ and all normal lung specimens were correctly classified 
as ‘healthy’. Since there were no LCC or other types of NSCLC in the Duke 
University data set, we only used the ADC and SCC signature genes for 
histological classification. For 84% of Duke University samples, the prediction 
by the 68-gene ADC/SCC signature was consistent with the reported histology 
diagnosis. When the LCC signature was included in the prediction analysis, 
this percentage decreased to 83%: 2 samples were classified as LCC (Fig. 4B). 
Follow-up data were available for 89 of 96 patients in the Duke University 
cohort, and we calculated the prognostic predictor for these patients using the 
17-gene survival signature and the predictive model. The difference in the 
hazard of death between the patient groups with a predicted good prognosis 
and the group with a poor prognosis was 2.44-fold, with a significance of 
p-value = 1.9E-03 by log-rank test. A Kaplan-Meier curve of overall survival 
is shown in Fig. 5B. If the Erasmus MC patient cohort is combined with the 
Duke University cohort, the p-value reduces to 2.6E-7.
Comparison with other prognostic gene expression signatures
A number of gene expression profiling-derived prognostic predictors have 
been previously reported for NSCLC [14-20]. These signatures were derived 
from a wide variety of technological approaches (Supplementary Table 8). We 
assessed the performance of 14 signatures from 6 different publications on 
the Erasmus MC and Duke University data sets (Supplementary Methods and 
Supplementary Table 8). For each publication, the results obtained with the 
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Figure 4. Prediction of histology subtype of Erasmus MC and Duke University 
NSCLC samples
A. correlation dendrogram generated by agglomerative hierarchical clustering of 
all 91 Erasmus MC NSCLC samples using the 75 probe set histology signature. 
Histo-pathological diagnosis of the initial and second review, and prediction of 
histology subtype by Prediction Analysis of Microarrays using the 75- and 518 probe 
set histology signatures, are shown by colored blocks.  B. correlation dendrogram 
generated by agglomerative hierarchical clustering of all 96 Duke University NSCLC 
samples using the 75 probe set histology signature. The reported histo-pathological 
diagnosis, and prediction of histology subtype by Prediction Analysis of Microarrays 
using the 75- and 518 probe set histology signatures, are shown by colored blocks. 
75AS and 518AS: prediction without the LCC genes in the histology signatures, using 
68 and 329 genes respectively (see Supplementary Tables 3 and 4).
signature yielding the best stratification are displayed in Kaplan-Meier curves 
(Supplementary Fig. 1). Performance of the 6-gene signature of Boutros et al 
[20] was reasonable on the Duke University cohort (p-value 0.016) but not 
on the Erasmus MC cohort (p-value 0.69). The 41-gene signature of Shedden 
et al. was developed for ADC samples [15]. It performed unsatisfactory on 
the complete Erasmus MC and Duke University cohorts (p-values 0.113 and 
0.158 respectively). However, if the analysis was limited to samples classified 
as ADC by our histology signature, this was the only prognostic signature that 
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Figure 5.  A 17 probe set signature predicts patient survival time
Kaplan-Meier curves for A. 82 Erasmus MC NSCLC patients and B. 89 Duke 
University NSCLC patients fitted by their risk assignments based on the 17 probe set 
survival signature. The high- and low-risk groups differ significantly, indicated by 
the p-values. Grey bars indicate patients at last follow-up, still alive.
performed well on both cohorts (Erasmus MC p-value 0.016, Duke University 
p-value 0.019). 
Discussion
Here, we defined a set of molecular classifiers for NSCLC. These classifiers 
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were developed with the Erasmus MC cohort of NSCLC patients, and validated 
using the independent Duke University cohort. The tumor signature gene set 
can be used to distinguish NSCLC from unaffected lung tissue. The histology 
signature gene set may aid in the histo-pathological classification of NSCLC. 
In addition, we identified a survival signature gene set that predicts overall 
patient survival. 
Potential for improved NSCLC classification
The histological diagnosis of LCC is based on exclusion of the other types 
of NSCLC. As a result, this subtype of NSCLC is highly heterogeneous in 
histopathology and clinical presentation. LCC accounts for about 16% of 
NSCLC cases. By applying special stains and electron microscopy it has 
been shown that many cases of LCC are poorly differentiated ADC or SCC 
[22]. The difficulty in distinguishing LCC from other NSCLC by routine 
histopathology results in considerable variation in the classification of NSCLC 
cases. In contrast, molecularly defined NSCLC subtypes display distinct gene 
expression profiles. For instance, a number of well-known SCC markers, such 
as TP63, PERP, keratins, and SERPINB, were uniformly expressed among 
a subset of the LCC samples, suggesting that these were actually SCC. In 
addition, expression profiling revealed that some of the tumors diagnosed 
as SCC display neuroendocrine characteristics, indicating that these were 
neuroendocrine tumors. Thus, the molecular signatures reveal specific features 
of the tumors. This could be used to improve the classification of NSCLC 
tumors, especially in histologically heterogeneous tumors where the signatures 
would identify the most characteristic molecular features of the samples.
A 17-gene signature set predicts survival
We have identified a small set of genes that predicts survival time independent 
of histo-pathological tumor type. Multivariate proportional hazard analysis that 
included age, pack years, gender, Forced Expiratory Volume 1, tumor stage, 
tumor cell content, tumor histology, and tumor size indicates that the 17-gene 
signature set is the strongest predictor of the likelihood of death. Importantly, 
the performance of this molecular predictor was similar in an independent 
NSCLC patient cohort, indicating its reproducibility and potential for practical 
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application in the clinical setting.
Divergence of prognostic gene expression signatures
Potti et al. [21] developed a metagene model to predict the risk of recurrence for 
individual patients. The model was predictive for the major types of NSCLC 
– ADC and SCC, and performed reasonably satisfactory in two independent 
patient cohorts. Confounding components of the metagene models contain 
over 100 genes. These attributes complicate the direct comparison of the 
metagenes to survival signatures derived from other studies. As such, the genes 
in the metagene model have no predictive power for survival analysis (data not 
shown). 
 It has been noted before that there is very little, if any, overlap between 
the reported prognostic signatures for NSCLC [19, 23]. Remarkably, there is 
not a single gene shared by the 7 signatures tested here (the 6 best performing 
previously reported signatures and our 17-gene signature). This has been 
attributed to the notion that the space from which such minimized signatures 
can be derived is large [19, 20] and hence there are many different possible 
outcomes depending on the particular dataset and bioinformatics approaches 
taken. For instance, although outcome signatures make predictions beyond 
histological subtype, it is still possible that genes in the signature are histology-
related. When these signatures are applied to other datasets with different 
tumor composition, they do not necessarily reflect clinical risk. The 41-gene 
prognostic signature of Shedden et al. [15] was developed with ADC samples. 
We found that stratification of the Erasmus MC and Duke University cohorts 
by this signature is histology-dependent, since it only performs satisfactorily 
on the ADC samples. For this analysis, we assigned tumor types in the Erasmus 
MC and Duke University cohorts with our histology signature. Thus, a scenario 
emerges where application of a histology signature is followed by analysis 
with a tumor type-specific prognostic classifier. Clearly, it is important to test 
whether prognostic classifiers of NSCLC are operative beyond histological 
criteria. 
Alternatively, prognostic classifiers transcending tumor histology 
would be more straightforward to use. To develop these, different tumor types 
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and subtypes should be included in the experimental set-up. Our dataset covers 
a relatively broad spectrum of NSCLC, and we have validated the signatures 
using independent samples profiled on the identical platform [21]. The lack 
of availability of raw microarray data (.CEL files) precludes validation of our 
signatures using more independent NSCLC cohorts; the complex issue of cross-
platform meta-analysis [16, 24] is beyond the scope of this paper. Nonetheless, 
our survival signature performed well compared to those previously reported 
[14-16, 18-20] when tested on the Erasmus MC and Duke University cohorts. 
We note that although the Duke University samples are clearly separated from 
the Erasmus MC samples in unsupervised analysis (Supplementary Fig. 2) our 
signatures still perform well on the Duke University data (e.g. Figs. 4B and 
5B), indicating that they are robust.
In conclusion, the sets of molecular markers identified in this report 
reveal histo-pathological attributes of NSCLC. These gene signatures might 
provide clinically relevant information for NSCLC, transcending traditional 
histological classification and patient outcome prediction.
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Supplementary Methods
Patient enrolment
Samples from patients recruited in this study were obtained from two Erasmus 
MC collections: the Tissue Bank and the Department of Internal Oncology. 
All lung tumor samples and adjacent non-cancerous specimens were collected 
from patients who had undergone curative surgical resection between 1992 
and 1998 (Internal Oncology), or between 1996 and 2004 (Tissue Bank) at the 
Erasmus MC. Tissues were collected and studied under an anonymous tissue 
protocol approved by the local medical ethical committee of the institution. 
There were 91 patients with NSCLC included in our analysis.
 The study comprised two independent validation sets. The first set 
included 6 normal lung tissues which were transcriptionally profiled by 
Affymetrix U133 plus 2.0 array (GSE3526). The second set comprised a 
cohort of 96 NSCLC patients collected at Duke University, including 50 ADC 
and 46 SCC samples [12]. Patient characteristics and the original microarray 
.CEL files were downloaded from http://data.genome.duke.edu/LungPotti.php. 
Eighty-nine out of those samples had relevant follow-up data available and 
were used for validating the performance of our survival signature. 
Histopathological analysis
All tumor samples were independently reviewed by two pathologists. The cohort 
included 32/24 adenocarcinomas (ADC), 27/16 squamous cell carcinomas 
(SCC), and 13/24 large cell carcinomas. The remaining patients presented 
with rarer types of lung tumors, such as bronchioloalveolar (BAC), carcinoid 
(CAR), mixed adeno-squamous, or unknown. In the cohort of patients, over 
57 percent had a known smoking history, with an average of 36.7 pack years. 
Of the 91 NSCLC patients, 51 were at stage I, 21 were at stage II, and 10 were 
at either stage III or IV. Three patients displayed distal metastases at the time 
of diagnosis. In addition, eight patients developed multiple primary tumors at 
different sites originating from the same cell type or different cell types, either 
synchronously or non-synchronously. Three had undergone neo-adjuvant 
radiation or chemotherapy before the surgery. Patient and tumor characteristics 
are listed in Table 1.
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Definining the training and validation sets
All samples were divided into two subsets, the training set and the validation 
set, and the former was used to identify NSCLC related molecular signatures.
As a result, thirty-six ‘core’ normal tissues were included in the training set, 
which showed strong similarities in global gene expression profile with each 
other and appeared in the core of normal lung cluster in an unsupervised 
clustering. Tumor samples were divided according to the two independent 
histopathological reviews, cancer cell contents, and degree of tumor 
differentiation.
 For tumor samples, those from patients with a complete clinical record 
were assigned into the training set. Samples were excluded from the training 
set if they fell into anyone of the following cases, 
From patients who developed multiple primary tumors;1. 
Received chemotherapy or radiotherapy prior to the surgery;2. 
Tumor cell content < 60%;3. 
 To develop histology signatures, additional criteria were employed 
to create a super training set to sketch a precise histological profile. Tumor 
samples had to meet below conditions:
Consistent classification between two histopathological reviews;1. 
No cell type heterogeneity;2. 
 As a result, forty-four tumor samples were included in the training set, 
and twenty-three composed the super training set.
 The remaining samples were used as a separate dataset for validating 
gene signatures identified by the training set. They were either from patients 
lacking complete clinic information or rejected by the above inclusion criteria, 
including eight LCC and five of rare types of NSCLC samples with a high 
level of cell type heterogeneity, and 19 percent (17 out of 91) of tumor samples 
had a discrepancy in histopathological classification.s
Total RNA isolation
The samples used in this study were fresh frozen tissues. Dissected tumors 
and adjacent normal tissues were snap-frozen in liquid nitrogen precooled 
isopentane immediately after the surgical resection, and stored at –196°°C or 
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–80 °C until RNA extraction. Specimens were sectioned in Cryostat into slices 
of 25 µm thick for RNA extraction. For each specimen, two thinner sections 
(10 µm) were taken at the start and end of collection, and used to determine 
the percentage of tumor cells. Samples were homogenized with a mortar 
and pestle in TRI Reagent (Invitrogen, Carlsbad, CA), and then incubated at 
room temperature for 5 minutes before adding 0.2 µl of chloroform for each 
1ml sample. After centrifuging at full speed (12000 rpm) for 20 minutes, the 
supernatant containing the RNA was precipitated and centrifuged with iso-
propanol. The resultant RNA pellets were washed with 75% ethanol and solved 
in RNase-free water. If applicable, they were stored at –80 °C for further 
usage. 
Assessment of RNA quality and concentration
The integrity if the isolated total RNA was verified on the Agilent 2100 
BioAnalyzer (Agilent Technologies, Palo Alto, CA). Samples were kept for 
further processes if the 28s/18s ratio of its RNA was lower than 1.2. The 
concentrations of the RNAs were measured with a NanoDrop ND-111 UV-
VIS spectrophotometer. 
cRNA amplification and labelling
Double strand (ds) cDNA synthesis was performed according to the standardized 
protocol for One-Cycle cDNA synthesis from Affymetrix (Santa Clara, CA). 
Approximately 5 µg of total RNA was first converted to single strand cDNA in 
a 20 µl First-Strand Reaction Mix, containing poly-A control RNA, 100 µmol 
T7-Oligo Primer, 1x first strand buffer, 0.2 mol DTT 10 mmol dNTP mix and 
SuperScript II. In detail, the sample RNA, the poly-A control RNA and the T7-
Oligo Primer were mixed and incubated for 10 min at 70 °C. Secondly, the first 
strand buffer, the DTT and the dNTP mix were added and incubated for 2 min 
at 42 °C, followed by adding SuperScript II and incubation of 1 hour at 42 °C. 
The ds cDNA was prepared from the resultant First-Strand Reaction Mix, mixed 
with 1x second strand reaction buffer, 30 mmol dNTP mix, E.coli DNA ligase, 
E.coli DNA Polymerase I and RNaseH. The mix was incubated for 2 hours at 
16 °C, then supplemented with T4 DNA Polymerase, and then incubated for 
another 5 minnutes at 16 °C. The reaction was stopped by the addition of EDTA 
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to a final concentration of 5 µM. The Sample Cleanup Module and GeneChip 
IVT Labeling Kit from Affymetrix were used to purify the synthesized ds 
cDNA, which was used to generate biotin-labeled cRNA, in the presence of 1x 
IVT Labeling buffer, IVT Labeling NTP Mix, IVT Labeling Enzyme Mix and 
RNase-free water in a total volume of 40 µl. After an incubation of 16 hours at 
37 °C, the concentration and quality of the labelled cRNA were checked with 
NanoDrop ND-1000 UV-VIS spectrophotometer. An A260/A280 ratio between 
1.9 and 2.1 was considered acceptable. Approximately 20 µg cRNA per array 
was fragmented to an average size of 35-200 nucleotides by heating at 94 °C 
for 35 min, in the presence of a 1x Fragmentation Buffer in a total volume of 
40 µl. The undiluted, fragmented samples were stored at –20 °C before being 
subjected to hybridization. 
Hybridization 
Hybridization was conducted following Affymetrix instruction for GeneChip® 
Human Genome U133 plus 2.0 array. The GeneArray scanner 3000 (Affymetrix) 
was then employed to detect the hybridization signals.
Preprocessing microarray data
Array Quality Control
Microarrays that did not pass the quality assessment were removed from 
further analyses. The quality metrics used to exclude microarrays was the 
statistics summary calculated by the GCOS algorithm during the processing of 
probe-level data. The primary inclusion criteria include: all arrays had to have 
comparable noise values (Raw Q, measurement for the pixel-to-pixel variation 
of probe cells on the chip); background values were within the range of 20 to 
100; percent of present probe sets on the array should not be below 45%. The 
other criteria were: arrays with extremely high or low values for any of these 
parameters, e.g. values beyond the range of standard deviation ± median, were 
excluded; signal ratio of ≤3 of the 3’ / 5’ probe sets for GAPDH and Actin were 
used as a cut-off; labelling and hybridization were controlled by using standard 
spike-in controls according to the Affymetrix protocol; if global scaling was 
applied, the scaling factors for each array were within a three-fold range.
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Data normalization
Microarray data was processed at two levels: probe level and probe set level.
At probe level by quantile normalization1. 
RMA (Robust Multi-Array average) is an integrated algorithm comprising 
background adjustment, quantile normalization, and expression summarization 
by median polish [1]. The intensities of mismatch probes were entirely ignored 
due to their spurious estimation of non-specific binding. The intensities were 
background-corrected in such a way that all corrected values must be positive. 
The RMA algorithm utilized quantile normalization in which the signal 
value of individual probes was substituted by the average of all probes with 
the same rank of intensity on each chip/array. Finally Tukey’s median polish 
algorithm was used to obtain the estimates of expression for normalized probe 
intensities.
At probe set level by Global Scaling (GCOS v1.4)2. 
This algorithm was a summary method embedded in GeneChip Operating 
Software (GCOS) from Affymetrix, and fully described in the data_analysis_
fundamentals_manual. The signal intensity of each probe was firstly corrected 
by the overall background.  The differences between perfect match (PM) and 
mismatch (MM) probes were examined by using background-adjusted intensi-
ties for each probe pair. The significance of the differences between PM and 
MM probe sets was reflected by a p-value calculated by one-sided Wilcoxon-
signed rank test. The final signal for a probe set was assigned as the one-step 
biweight estimate of the combined differences of all probe pairs belonging to 
one probe set. The trimmed mean signal of each array was then scaled to the 
same Target Intensity (e.g. 250) by a global method to minimize technique-
derived discrepancies.
Other transformations
Intensities of probe sets lower than 30 were reset to 30. The geometric mean 
for each probe set was calculated across all samples or for each subgroup of 
samples firstly and then across all samples (OmniViz). The intensity values of 
individual probe sets in each sample were then displayed as the log 2 of the 
deviations to the calculated geometric means. 
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Probe sets filtering
Probe sets were involved in further analysis only if their expression levels 
deviated from the overall mean in at least one array by a minimum factor of 
2.5, because the remaining data were unlikely to be informative. The result 
was that 43,160 probe sets were eliminated, and 11,515 probe sets remained 
for further analysis.
Unsupervised clustering and visualization of gene/sample similarity
Clustering was performed without taking into account any external information 
such as histology subtypes and tumor stages, with each of the selected 
11,515 probe sets using the K-means algorithm (OmniViz). Similarities were 
measured by magnitude and shape (Euclidean distance). Pair-wised similarities 
between samples were sorted and visualized by the Pearson Correlation Matrix 
(OmniViz). The order of clusters and individual samples within each cluster 
was sorted according to the Pearson Correlation Coefficient.
Statistical analysis 
The resulting 11,515 probe sets from the filtering step was the starting point 
for all supervised analyses which, for instance, correlated gene expression with 
the clinical variables such as the histological subtype. Two-Class comparison 
analysis was performed by using Significance Analysis of Microarray (SAM), 
integrated in OminiViz version 5.1. Class prediction analysis was performed 
with the use of Prediction Analysis of Microarrays (PAM) software, integrated 
in BRBArray version 3.8.  Clustering was performed using the Spotfire 
DecisionSite software (TIBCO, Palo Alto, CA). The samples were clustered 
with various signatures using the Weighted Pair-Group Method algorithm and 
similarity measured by Euclidean distance or correlation.
Class comparison
SAM discovered differentially expressed genes among different sample 
classes, e.g. between non-cancerous tissues and tumors or between a particalur 
histology subtype and the remaining samples [2]. Firstly this algorithm 
calculated the different expression for each gene between classes relative to 
the variation expected in the mean difference. To correct multiple testing, false 
discovery rate (FDR) was controlled by randomly permutating the classes of 
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samples 100 times. Signature probe sets for assigned classes were selected by 
a change factor of 2 and a FDR of less than 1 percent. The class comparisons 
were performed with both RMA- and GCOS-processed data. The common 
probe sets identified by both sets of data were selected as the final signatures.
Class prediction
The resultant signatures from Class Comparison were tested by the nearest 
shrunken centroids algorithm (PAM) to identify subgroups of genes that best 
characterized the predefined classes [3]. The prediction accuracy of optimized 
signatures was determined by performing “leave-one-out” cross validation 
within the training set, with one sample omitted each time and class label 
being predicted with other samples for the omitted sample [4]. The predictive 
models generated by the optimal subsets were subsequently applied to make 
predictions of classes for samples in the validation set, which were not 
involved in the corresponding class comparisons. The prediction accuracy on 
validation samples was calculated by comparing predicted class labels with 
the clinical histopathological diagnoses for those samples; samples without 
histopathological records were excluded from the calculations.
Survival analysis
Of 91 NSCLC samples, 82 have relevant follow-up data available. Therefore, 
those samples were included in survival analysis. 
 Two different approaches were used to determine whether the gene 
expression profile could predict the prognosis for NSCLC patients. In one 
approach, samples from patients who died of lung cancer within two years of 
surgical removal of tumors were assigned to the group of NSCLC with short-
time survival.  The long-time survival group consisted of samples from patients 
who survived for longer than 5 years. To avoid unexpected variances introduced 
by the failure of surgery or postoperative sequelae, those patients who died 
within six months of surgery were kept out of the analysis. Subsequently, the 
same analysis was performed conditionally for histological subtypes.
 As an alternative way, we developed a step-wise approach based 
on gene expression profiles to classify NSCLC with respect to prognostic 
outcome. Firstly, probe sets which were the most likely associated with patient 
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prognosis were selected among over 11,000 probe sets by their correlation 
with the defined survival time; A list of candidate probe-sets was created with 
probe-sets whose univariate p-values, testing the hypothesis that survival time 
is independent of the expression level for that gene, was smaller than 0.001 
by the Wald test in the Cox proportional hazards model [5]. A global test was 
performed with 1000 permutations to adjust p-values.
 In the analysis of the probability that patients would remain free of 
death, survival time (OS) was defined as the date of surgery to the time of event 
happened – death, or the date on which data were censored - the last follow-up 
visit.
 The resulting candidate survival probe-sets were subjected to a 
supervised principal component calculation described in details by Bair et al [6]. 
The computation of principal components was followed by Cox proportional 
hazards regression analysis using the computed principal components. As 
a result, a predictive prognosis model for NSCLC was determined, with 
regression coefficients derived from the Cox regression described above. With 
the developed model, a prognostic predictor was calculated for a NSCLC case 
whose expression profile was provided as the expression levels of selected 
probe-sets.
 The predictive value of the prognosis model was evaluated by 
performing “leave-one-out” cross-validation”, in which a single case was 
omitted each time and the entire procedure described above was performed to 
estimate prognosis predictor for the omitted case [6, 7]. This prognosis predictor 
value was compared and ranked relative to the prognosis predictors of cases 
included in the cross-validation training cases. Based on the predetermined 
cut-off percentile rank for defining the risk groups, the omitted case was placed 
into a risk group. This analysis was repeated until each sample was left out 
once, resulting in a set of unbiased prognosis prediction for all cross-validated 
samples.
 Having obtained unbiased prognosis predictors and consequent 
categorizing patients, the difference in the survival outcome between risk 
groups was estimated by log-rank Mantel-Cox test and plotted by Kaplan-
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Meier curve [8]. The analyses were performed with BRB-Array Tools (version 
3.8; R.Simon and A.P.Lam, National Cancer Institute, Bethesda, MD).
 To evaluate the prognostic value of the prognosis predictor relative to 
other clinical parameters, we used proportional hazard regression analysis with 
the defined survival time as dependent variable, death as the occurred event, 
and the last follow-up visit as the censored. The risk of death studied included 
age, tumor cell content (%), tumor size (diameter of tumor), smoking year, 
Forced Expiratory Volume 1, and gender, tumor histology, tumor grade, as well 
as computed prognosis predictor. The relation between them and the relative 
hazard ratio was tested with use of the Wald test. The 95% confidence interval 
for relative hazard ratios, and the p-values are listed in supplementary Table 
7. To compare the performance in predicting the overall OS, the proportional 
hazard regression model was built with either involving a specific parameter 
or not. The contribution of each parameter to the model was evaluated by chi-
square test and P-value was derived from the likelihood ratio test (Table 2) 
[5].
 The correlation between the survival signature and clinical parameters 
was evaluated using predicted risk as grouping variable and with independent 
samples t-test for continuous variables, or non-parametric test, Mann-Whitney 
and maximum possibility Wald-Wolfowitz test, for categorical variables and 
scalar variables (Supplementary Table 6). Statistical analyses were performed 
with SPSS 15.0 (SPSS, Chicago, IL). For each tumor from NSCLC validation 
cohort, we calculated a prognosis predictor by fitting the predetermined 
predictive model with expression of the 17 probe sets. Patients were predicted 
with high-risk of death if their prognosis predictor percentile ranking was above 
the 60th, as determined in the procedure of identifying prognosis signature using 
training samples.
Comparison with published prognostic signatures
If the original prognostic predictors were provided as gene symbols [9-13], 
we retrieved gene expression for the Erasmus MC and Duke University 
cohorts as follows. First, genes were mapped to the Affymetrix U133 plus 2.0 
chip, and the corresponding expression data from all relevant probe sets was 
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extracted (Supplementary Table 8). Next, probe set level data was converted 
to gene level data by averaging probe sets targeting the same genes. Due to the 
variation between platforms, 4 genes from the Roepman et al [12] signature 
were missing from the Affymetrix U133 plus 2.0 chip, we used the remaining 
68 genes.
 When the original prognostic predictors were supplied as probe sets 
[14, 15], either from Affymetrix U133A or U133 plus 2.0 arrays, the data was 
kept at probe set level. The Affymetrix HuGeneFL chip used by Beer et al 
/ Guo et al [14, 15] deviates too much from the U133 plus 2.0 chip and we 
therefore used gene symbols to re-map the data to the U133 plus 2.0 chip.
Some studies provide multiple signature sets [10, 14, 15], in which case each 
signature set was tested. For all re-evaluations, a cut-off at the 50th and 60th 
percentile was used for dividing the two risk groups. We only show the results 
for the best stratification obtained (Supplementary Fig. 2).
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Supplementary Figure 1. Survival prediction by published prognostic signatures
Kaplan-Meier curves for the best performing signatures (by P-value) are shown for 
82 Erasmus MC patients (left) and 89 Duke University NSCLC patients (right), fitted 
by their risk assignments. Grey bars indicate patients at last follow-up, still alive.  P-
values are between brackets if overall survival of the low risk group is actually lower 
than that of the high risk group. (continued on next page)
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Supplementary Figure 1 (continued).  Survival prediction by published prognostic 
signatures
Kaplan-Meier curves for the best performing signatures (by P-value) are shown for 
82 Erasmus MC patients (left) and 89 Duke University NSCLC patients (right), fitted 
by their risk assignments. Grey bars indicate patients at last follow-up, still alive.  P-
values are between brackets if overall survival of the low risk group is actually lower 
than that of the high risk group.
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Supplementary Figure 2.  Correlation view of Erasmus MC and Duke University 
NSCLC samples
In total 187 tumor samples from the Erasmus MC (n=91) and Duke University (n=96) 
cohorts are shown. Pairwise correlations between any two samples are displayed, 
based on 3495 informative probe sets. Histological classification of the samples, and 
the collection source, are depicted along the diagonal. The key to the color code is 
shown at the bottom. Histo-path_E1 & Histo-path_E2: initial and second histo-path-
ological review of Erasmus MC samples. Histo-path_D: histo-pathological review 
of Duke University samples; Histo-path_P-518 and Histo-path_P-75: predictions by 
PAM of histological subtypes using the 518 and 75 probe set signatures, respectively 
(see Supplementary Tables 3 and 4).
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Legend to Supplementary Tables
Supplementary Tables 1 and 2
T:N ratio Ratio of average expression in NSCLC samples / normal lung 
tissue
T mean 2log transformation of mean expression value in NSCLC samples 
(average of all NSCLC and normal lung tissue = 0).
N mean 2log transformation of mean expression value in normal lung 
tissue samples (average of all NSCLC and normal lung tissue = 
0).
T SD Standard deviation of mean expression value in NSCLC samples
N SD Standard deviation of mean expression value in normal lung tissue 
samples
Supplementary Tables 3 and 4
ADC:OT ratio Ratio of average expression in ADC samples / the other NSCLC 
samples (SCC and LCC)
SCC:OT ratio Ratio of average expression in SCC samples / the other NSCLC 
samples (ADC and LCC)
LCC:OT ratio Ratio of average expression in LCC samples / the other NSCLC 
samples (ADC and SCC)
ADC mean 2log transformation of mean expression value in ADC samples 
(average of all Erasmus MC samples = 0).
SCC mean 2log transformation of mean expression value in SCC samples 
(average of all Erasmus MC samples = 0).
LCC mean 2log transformation of mean expression value in LCC samples 
(average of all Erasmus MC samples = 0).
ADC SD Standard deviation of mean expression value in ADC samples
SCC SD Standard deviation of mean expression value in SCC samples
LCC SD Standard deviation of mean expression value in LCC samples
Supplementary Tables 5, 6, 7 and 8
Supplementary Tables 5, 6, 7 and 8 are self-explanatory.
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SUPPLEMENTARY TABLE 1: NSCLC TUMOR SIGNATURE
Probe set Gene 
Symbol
Gene 
Symbol 
before 2008
T:N 
Ratio
T 
Mean 
N 
Mean 
T 
SD
N 
SD
q 
value
213664_at SLC1A1 SLC1A1 0.13 -1.65 1.92 1.41 0.57 0.01
226625_at TGFBR3 TGFBR3 0.18 -1.08 1.70 0.98 0.43 0.01
227826_s_at --- SORBS2 0.14 -1.28 1.90 1.07 0.62 0.01
227874_at EMCN 0.10 -1.58 2.24 1.16 0.65 0.01
228504_at --- 0.10 -1.77 2.45 1.53 0.44 0.01
229127_at JAM2 ATP5J 0.16 -1.21 1.71 0.83 0.45 0.01
229308_at --- 0.13 -1.42 2.11 1.13 0.55 0.01
229339_at --- 0.32 -0.67 0.95 0.33 0.44 0.01
229641_at --- 0.15 -1.25 1.76 0.83 0.35 0.01
230711_at --- EPAS1 0.19 -0.86 1.46 0.55 0.76 0.01
233392_at --- 0.19 -0.92 1.43 0.42 0.71 0.01
235108_at --- 0.18 -0.96 1.66 0.83 0.62 0.01
235570_at --- 0.21 -1.10 1.46 1.03 0.30 0.01
235670_at STX11 STX11 0.16 -1.31 1.79 1.02 0.44 0.01
235915_at --- 0.15 -1.07 1.36 0.39 1.04 0.01
236065_at --- 0.13 -1.40 1.72 0.88 0.74 0.01
236383_at --- 0.15 -1.13 1.60 0.58 0.77 0.01
236936_at --- 0.13 -1.39 1.79 0.81 0.59 0.01
238178_at --- 0.13 -1.06 1.89 0.68 0.83 0.01
239262_at --- PRSS23 0.15 -1.15 1.67 0.64 0.55 0.01
239849_at --- 0.10 -1.21 1.99 0.59 1.02 0.01
242009_at SLC6A4 0.06 -1.66 2.97 1.07 1.52 0.01
242500_at --- 0.17 -0.99 1.67 0.71 0.60 0.01
242868_at --- EPAS1 0.16 -1.16 1.75 1.14 0.62 0.01
243172_at --- 0.18 -0.94 1.60 0.58 0.56 0.01
243813_at --- 0.15 -1.05 1.75 0.59 0.77 0.01
243818_at SFTA1P 0.14 -1.35 1.86 0.93 0.39 0.01
204719_at ABCA8 ABCA8 0.09 -1.83 2.36 1.32 0.39 0.01
223395_at ABI3BP ABI3BP 0.16 -1.33 1.76 1.27 0.30 0.01
206069_s_at ACADL ACADL 0.11 -1.35 1.87 0.64 0.80 0.01
220677_s_at ADAMTS8 ADAMTS8 0.12 -1.26 1.95 0.69 0.67 0.01
235649_at ADAMTS8 ADAMTS8 0.08 -1.73 2.45 1.11 0.58 0.01
203865_s_at ADARB1 ADARB1 0.15 -1.25 1.70 0.86 0.38 0.01
209612_s_at ADH1B ADH1B 0.09 -2.29 2.69 2.20 0.55 0.01
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209613_s_at ADH1B ADH1B 0.09 -2.32 2.81 2.29 0.46 0.01
209614_at ADH1B ADH1B 0.11 -1.49 1.78 0.75 0.61 0.01
229309_at ADRB1 ADRB1 0.08 -1.90 2.65 1.59 0.72 0.01
206170_at ADRB2 ADRB2 0.16 -1.34 1.72 1.16 0.53 0.01
210081_at AGER AGER 0.06 -2.06 3.05 1.39 0.54 0.01
217046_s_at AGER AGER 0.10 -1.41 2.25 0.86 0.51 0.01
202759_s_at
AKAP2 /// 
PALM2 /// 
PALM2-
AKAP2
PALM2-
AKAP2 0.20 -1.13 1.46 0.98 0.43 0.01
226694_at
AKAP2 /// 
PALM2 /// 
PALM2-
AKAP2
PALM2-
AKAP2 0.24 -0.95 1.29 0.86 0.36 0.01
224339_s_at ANGPTL1 ANGPTL1 0.27 -0.81 0.96 0.36 0.73 0.01
231773_at ANGPTL1 ANGPTL1 0.23 -0.93 1.15 0.52 0.64 0.01
218418_s_at KANK2 ANKRD25 0.28 -0.90 1.08 0.71 0.30 0.01
213715_s_at KANK3 ANKRD47 0.21 -0.86 1.43 0.60 0.59 0.01
222608_s_at ANLN ANLN 21.61 1.55 -2.35 1.67 0.54 0.01
204894_s_at AOC3 AOC3 0.15 -1.38 1.73 1.14 0.36 0.01
206167_s_at ARHGAP6 ARHGAP6 0.22 -1.07 1.72 1.14 0.43 0.01
206030_at ASPA ASPA 0.21 -0.97 1.21 0.43 0.60 0.01
219918_s_at ASPM ASPM 16.04 1.39 -2.22 1.52 0.58 0.01
203296_s_at ATP1A2 ATP1A2 0.20 -0.94 1.40 0.60 0.67 0.01
228434_at BTNL9 BTNL9 0.11 -1.33 2.29 1.23 0.73 0.01
203571_s_at C10orf116 C10orf116 0.13 -1.58 1.85 1.32 0.47 0.01
218723_s_at C13orf15 C13orf15 0.17 -1.22 1.71 0.97 0.30 0.01
235568_at C19orf59 TRAPPC5 0.10 -1.86 2.45 1.44 0.64 0.01
239349_at C1QTNF7 C1QTNF7 0.14 -1.24 1.82 0.68 0.74 0.01
213900_at C9orf61 C9orf61 0.15 -1.26 1.83 0.93 0.38 0.01
206208_at CA4 CA4 0.17 -1.03 1.68 0.70 0.52 0.01
206209_s_at CA4 CA4 0.08 -1.60 2.64 1.03 0.55 0.01
203065_s_at CAV1 CAV1 0.15 -1.37 1.85 1.21 0.43 0.01
212097_at CAV1 CAV1 0.16 -1.33 1.70 1.11 0.24 0.01
203323_at CAV2 CAV2 0.14 -1.44 1.88 1.32 0.35 0.01
214710_s_at CCNB1 CCNB1 14.31 1.33 -2.18 1.32 0.48 0.01
202705_at CCNB2 CCNB2 14.02 1.37 -2.02 1.45 0.47 0.01
228766_at CD36 CD36 0.11 -1.78 2.21 1.46 0.72 0.01
202870_s_at CDC20 CDC20 17.30 1.50 -2.15 1.53 0.45 0.01
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204677_at CDH5 CDH5 0.16 -1.19 1.75 0.98 0.39 0.01
214135_at CLDN18 CLDN18 0.07 -2.03 2.83 1.75 0.35 0.01
232578_at CLDN18 CLDN18 0.08 -2.12 2.85 1.53 0.84 0.01
213317_at CLIC5 CLIC5 0.08 -1.99 2.77 1.79 0.42 0.01
217628_at CLIC5 CLIC5 0.21 -0.93 1.39 0.59 0.67 0.01
219866_at CLIC5 /// CLIC5 0.12 -1.52 2.15 1.18 0.56 0.01
211343_s_at COL13A1 COL13A1 0.21 -1.01 1.38 0.78 0.44 0.01
230867_at COL6A6 COL6A6 0.12 -1.58 2.04 1.31 0.54 0.01
227178_at CUGBP2 CUGBP2 0.21 -1.07 1.36 0.81 0.29 0.01
1555497_a_
at CYP4B1 CYP4B1 0.09 -1.69 2.20 1.26 0.93 0.01
210762_s_at DLC1 DLC1 0.19 -1.20 1.64 1.19 0.48 0.01
224822_at DLC1 DLC1 0.16 -1.33 1.79 1.20 0.40 0.01
203764_at DLGAP5 DLG7 18.09 1.40 -2.27 1.53 0.36 0.01
205003_at DOCK4 DOCK4 0.27 -0.93 1.19 0.90 0.32 0.01
219597_s_at DUOX1 DUOX1 0.15 -1.29 1.74 1.08 0.60 0.01
204642_at S1PR1 EDG1 0.20 -1.00 1.37 0.64 0.57 0.01
204271_s_at EDNRB EDNRB 0.11 -1.39 2.02 1.00 0.63 0.01
204273_at EDNRB EDNRB 0.08 -1.81 2.49 1.26 0.68 0.01
206701_x_at EDNRB EDNRB 0.10 -1.45 2.14 0.88 0.66 0.01
228967_at EIF1 EIF1 0.27 -0.74 1.23 0.62 0.48 0.01
219436_s_at EMCN EMCN 0.15 -1.31 1.74 1.10 0.69 0.01
222885_at EMCN EMCN 0.17 -1.20 1.70 1.12 0.52 0.01
203980_at FABP4 FABP4 0.09 -2.11 2.66 1.72 0.63 0.01
207547_s_at FAM107A FAM107A 0.10 -1.28 2.08 0.69 0.69 0.01
209074_s_at FAM107A FAM107A 0.08 -1.64 2.67 1.21 0.71 0.01
205866_at FCN3 FCN3 0.07 -1.83 2.77 1.38 0.90 0.01
201540_at FHL1 FHL1 0.14 -1.46 1.94 1.22 0.27 0.01
210299_s_at FHL1 FHL1 0.11 -1.77 2.29 1.40 0.51 0.01
220170_at FHL5 FHL5 0.16 -1.14 1.63 0.81 0.72 0.01
206742_at FIGF FIGF 0.08 -1.77 2.45 1.20 0.67 0.01
1556325_at FILIP1 FILIP1 0.17 -1.17 1.73 1.00 0.61 0.01
228268_at FMO2 FMO2 0.12 -1.45 2.17 1.33 0.48 0.01
205935_at FOXF1 FOXF1 0.17 -1.09 1.62 0.84 0.59 0.01
228568_at
GCOM1 /// 
GRINL1A Gcom1 0.15 -1.16 1.72 0.74 0.60 0.01
206159_at GDF10 GDF10 0.12 -1.26 1.84 0.50 0.67 0.01
206102_at GINS1 GINS1 15.94 1.47 -2.11 1.46 0.46 0.01
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238222_at GKN2 GKN2 0.08 -1.92 2.58 1.28 0.57 0.01
230360_at GLDN GLDN 0.11 -1.38 2.09 0.99 0.80 0.01
209469_at GPM6A GPM6A 0.11 -1.58 2.40 1.12 0.48 0.01
209470_s_at GPM6A GPM6A 0.09 -1.75 2.62 1.25 0.58 0.01
232267_at GPR133 GPR133 0.20 -1.25 1.79 1.38 0.30 0.01
204396_s_at GRK5 GRK5 0.24 -0.87 1.44 0.79 0.35 0.01
238018_at FAM150B 0.09 -1.40 1.91 0.69 0.96 0.01
213069_at HEG1 HEG1 0.28 -0.88 1.15 0.78 0.32 0.01
203914_x_at HPGD HPGD 0.11 -1.73 2.18 1.64 0.62 0.01
211548_s_at HPGD HPGD 0.11 -1.81 2.26 1.56 0.67 0.01
205700_at HSD17B6 HSD17B6 0.12 -1.62 1.97 1.42 0.59 0.01
37512_at HSD17B6 HSD17B6 0.12 -1.62 2.08 1.43 0.61 0.01
230670_at IGSF10 IGSF10 0.18 -1.11 1.53 0.83 0.52 0.01
224061_at INMT INMT 0.12 -1.44 2.07 1.24 0.68 0.01
235666_at --- 0.14 -1.41 1.83 1.05 0.37 0.01
219064_at ITIH5 ITIH5 0.22 -1.12 1.40 0.92 0.38 0.01
219213_at JAM2 JAM2 0.23 -0.99 1.25 0.70 0.45 0.01
202503_s_at KIAA0101 KIAA0101 13.20 1.34 -2.16 1.31 0.75 0.01
209408_at KIF2C KIF2C 9.03 1.15 -1.70 1.20 0.38 0.01
206481_s_at LDB2 LDB2 0.18 -1.16 1.63 1.01 0.49 0.01
203766_s_at LMOD1 LMOD1 0.22 -0.94 1.31 0.71 0.52 0.01
220244_at LOH3CR2A LOH3CR2A 0.12 -1.35 1.98 0.94 0.69 0.01
220003_at LRRC36 LRRC36 0.19 -1.02 1.38 0.46 0.62 0.01
203362_s_at MAD2L1 MAD2L1 13.64 1.28 -2.05 1.37 0.45 0.01
228885_at MAMDC2 MAMDC2 0.07 -1.90 2.72 1.38 0.60 0.01
212713_at MFAP4 MFAP4 0.13 -1.43 1.86 1.08 0.67 0.01
219909_at MMP28 MMP28 0.23 -1.03 1.26 0.75 0.49 0.01
239272_at MMP28 MMP28 0.16 -1.43 1.57 0.98 0.49 0.01
239273_s_at MMP28 MMP28 0.26 -1.05 1.17 0.92 0.44 0.01
219091_s_at MMRN2 MMRN2 0.22 -0.96 1.36 0.69 0.38 0.01
236262_at MMRN2 MMRN2 0.19 -1.02 1.57 0.84 0.47 0.01
227417_at MOSC2 MOSC2 0.21 -1.11 1.38 0.88 0.35 0.01
226856_at MUSTN1 TMEM110 0.25 -0.86 1.20 0.61 0.65 0.01
212372_at MYH10 MYH10 0.29 -0.77 1.13 0.70 0.37 0.01
237206_at MYOCD MYOCD 0.23 -0.85 1.22 0.52 0.63 0.01
204641_at NEK2 NEK2 13.66 1.38 -1.92 1.37 0.29 0.01
223381_at NUF2 NUF2 14.93 1.43 -1.94 1.47 0.30 0.01
218736_s_at PALMD PALMD 0.18 -1.21 1.46 0.83 0.56 0.01
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227088_at PDE5A PDE5A 0.19 -1.15 1.42 0.82 0.47 0.01
209493_at PDZD2 PDZD2 0.13 -1.70 1.85 1.29 0.44 0.01
208981_at PECAM1 PECAM1 0.29 -0.84 1.14 0.77 0.30 0.01
206311_s_at PLA2G1B PLA2G1B 0.13 -1.46 1.96 1.04 0.73 0.01
227148_at PLEKHH2 PLEKHH2 0.15 -1.30 1.72 0.95 0.47 0.01
201578_at PODXL PODXL 0.29 -0.81 1.05 0.65 0.40 0.01
227006_at PPP1R14A PPP1R14A 0.17 -1.12 1.70 1.00 0.55 0.01
226380_at PTPN21 PTPN21 0.16 -1.23 1.73 0.96 0.52 0.01
205846_at PTPRB PTPRB 0.17 -1.13 1.65 0.85 0.63 0.01
230250_at PTPRB PTPRB 0.12 -1.46 2.11 1.25 0.59 0.01
205326_at RAMP3 RAMP3 0.15 -1.08 1.70 0.72 0.69 0.01
210550_s_at RASGRF1 RASGRF1 0.27 -0.91 1.03 0.68 0.59 0.01
205407_at RECK RECK 0.24 -1.01 1.29 0.88 0.42 0.01
243481_at RHOJ RHOJ 0.27 -0.79 1.13 0.57 0.61 0.01
226028_at ROBO4 ROBO4 0.15 -1.12 1.81 0.79 0.50 0.01
235849_at SCARA5 SCARA5 0.19 -1.10 1.19 0.67 0.86 0.01
236359_at SCN4B SCN4B 0.18 -0.97 1.64 0.76 0.77 0.01
222717_at SDPR SDPR 0.13 -1.44 2.21 1.36 0.51 0.01
215454_x_at SFTPC SFTPC 0.09 -1.85 2.38 1.39 0.51 0.01
226673_at SH2D3C SH2D3C 0.26 -0.80 1.18 0.60 0.57 0.01
218087_s_at SORBS1 SORBS1 0.19 -1.31 1.79 1.26 0.42 0.01
215918_s_at SPTBN1 SPTBN1 0.16 -1.08 1.75 0.74 0.39 0.01
227480_at SUSD2 SUSD2 0.11 -1.77 2.33 1.52 0.40 0.01
234310_s_at SUSD2 SUSD2 0.22 -0.95 1.30 0.62 0.51 0.01
209447_at SYNE1 SYNE1 0.26 -0.94 1.22 0.92 0.33 0.01
200911_s_at TACC1 TACC1 0.31 -0.82 1.04 0.77 0.21 0.01
204931_at TCF21 TCF21 0.08 -1.76 2.21 1.01 0.60 0.01
229529_at TCF21 TCF21 0.17 -1.08 1.54 0.68 0.69 0.01
206702_at TEK TEK 0.13 -1.35 1.97 1.00 0.48 0.01
219230_at TMEM100 TMEM100 0.07 -2.11 2.84 1.64 0.94 0.01
209904_at TNNC1 TNNC1 0.12 -1.45 2.35 1.30 0.47 0.01
221747_at TNS1 TNS1 0.19 -1.05 1.53 0.79 0.38 0.01
221748_s_at TNS1 TNS1 0.22 -0.98 1.51 0.97 0.33 0.01
206093_x_at
TNXA /// 
TNXB TNXB 0.15 -1.17 1.64 0.70 0.49 0.01
213451_x_at
TNXA /// 
TNXB TNXB 0.14 -1.19 1.76 0.70 0.51 0.01
216333_x_at
TNXA /// 
TNXB TNXB 0.14 -1.19 1.70 0.69 0.49 0.01
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201291_s_at TOP2A TOP2A 32.13 1.86 -2.84 1.65 0.82 0.01
201292_at TOP2A TOP2A 23.60 1.58 -2.47 1.60 0.41 0.01
210052_s_at TPX2 TPX2 17.03 1.38 -2.15 1.53 0.39 0.01
202954_at UBE2C UBE2C 15.20 1.42 -1.96 1.46 0.36 0.01
223229_at UBE2T UBE2T 12.18 1.31 -1.91 1.21 0.34 0.01
232122_s_at VEPH1 VEPH1 0.10 -1.76 2.19 1.19 0.55 0.01
220327_at VGLL3 VGLL3 0.16 -1.30 1.74 0.92 0.47 0.01
205019_s_at VIPR1 VIPR1 0.13 -1.08 2.05 1.00 0.94 0.01
222738_at WWC2 WWC2 0.18 -1.12 1.52 0.73 0.51 0.01
1555800_at ZNF385B ZNF533 0.12 -1.70 1.95 1.36 0.83 0.01
SUPPLEMENTARY TABLE 2:  NSCLC TUMOR SIGNATURE (SHORT)
Probe set Gene 
Symbol
Gene 
Symbol 
before 2008
T:N 
Ratio
T 
Mean 
N 
Mean 
T 
SD
N 
SD
q 
value
210081_at AGER AGER 0.06 -2.06 3.05 1.39 0.54 0.01
206209_s_at CA4 CA4 0.08 -1.6 2.64 1.03 0.55 0.01
209074_s_at FAM107A FAM107A 0.08 -1.64 2.67 1.21 0.71 0.01
238222_at GKN2 GKN2 0.08 -1.92 2.58 1.28 0.57 0.01
201291_s_at TOP2A TOP2A 32.13 1.86 -2.84 1.65 0.82 0.01
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SUPPLEMENTARY TABLE 5:  NSCLC PATIENT SURVIVAL 
SIGNATURE
Probe set Gene symbol correlation p value Cytoband
1553300_a_at DGKH 0.0009322 13q14.11
1557638_at -- 1.08E-05
201123_s_at EIF5A 0.0009121 17p13-p12
203634_s_at CPT1A 0.0004619 11q13.1-q13.2
206262_at ADH1C 0.0001821 4q21-q23
206581_at BNC1 0.0007771 15q25.2
206985_at HSD17B3 7.74E-05 9q22
208459_s_at XPO7 0.0005945 8p21
210839_s_at ENPP2 0.0009995 8q24.1
227115_at -- 0.0003025
231487_at COX8C 0.0007767 14q32.13
231916_at EXOSC6 0.0005624 16q22.1
232120_at EGFR 0.0007851 7p12
233044_at EGFR 6.40E-06 7p12
233488_at RNASE7 0.0001726 14q11.2
236646_at C12orf59 0.0003665 12p13.2
237510_at MYNN 7.12E-05 3q26.2
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  Predicted_LOW Predicted_HIGH p-value
  (n = 50) (n = 32)  
Age Mean 60.49 65.96 0.023
 SD 10.56 10.18  
Tumor cell % Mean 63.22 68.30 0.242
 SD 21.00 15.44  
Stage_I 34 17 0.197
 68.0% 53.1%  
Stage_II 11 9 0.366
 22.0% 28.1%  
Stage_III+IV 4 6 0.789
 8.0% 18.8%  
Smoking years Mean 33.75 39.88 0.014
 SD 10.98 10.50  
Gender  
Female 19 4 0.012
 38.0% 12.5%  
Male 31 28  
 62.0% 87.5%  
Forced Expiratory 
Volume 1 Mean 88.09 78.10 0.009
 SD 17.49 14.45  
Tumor size Mean 37.07 38.56 0.622
 SD 13.79 12.74  
Histology  
ADC 16 8 0.991
 32.0% 25.0%  
SCC 5 11 0.942
 10.0% 34.4%  
LCC 17 7 0.967
 34.0% 21.9%  
OTHER 12 6 0.975
  24.0% 18.8%  
Supplementary Table 6.  Association between the prognostic predictor 
and clinical parameters
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Supplementary Table 7.  Relation between variables 
and the relative hazard ratio 
 Wald test p-value
Age 1.68 0.20
Tumor cell % 0.95 0.33
Stage 3.80 0.05
Gender 0.00 0.99
Smoking years 0.08 0.78
Forced Expiratory Volume 1 0.54 0.46
Tumor size 0.02 0.90
Histology 2.43 0.12
Prognostic predictor 21.68 0.000003
Supplementary Table 8.  Prognostic signatures for NSCLC 
Publication NSCLC subtypes platform
# of genes in 
signature
genes (probe sets) 
present on Affy 
U133 plus 2.0
Chen et al. (2007) NEJM  
356, 11-20
ADC, SCC, 
other
9.6k cDNA  
home made
16 16 (55)
5 5 (18)
Beer et al. (2002) Nat Med 
8, 816-824  
Guo et al. (2008) CCR 14, 
8213-8220
ADC Affy HuGeneFL 35 35 (134)
Shedden et al. (2008) Nat 
Med 14, 822-827 ADC Affy U133A
A_>1000 not tested
B_52 50 (52)
C_26 23 (26)
D-42 36 (42)
E_1 1 (1)
F_41 37 (41)
G_38 36 (38)
H_313 249 (313)
Lee et al (2008) CCR 14, 
7397-7404 ADC, SCC
Affy U133 
plus 2.0
20 20 (20)
6 6 (6)
Roepman et al. (2009) CCR 
15, 284-290
ADC, SCC, 
other Agilent 44k 72 68 (224)
Boutros et al. (2009) PNAS 
106, 2824-2828 ADC, SCC QRT-PCR 6 6 (8)
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Abstract 
Pemetrexed effectiveness has been related to the expression of its target 
Thymidylate Synthase (TYMS). The more frequent resistance to Pemetrexed 
in lung squamous cell carcinoma (SCC) patients is ascribed to high level of 
TYMS. In this study, the gene expression level of TYMS and other targets of 
Pemetrexed was profiled in 91 non-small cell lung cancer (NSCLC) subjects 
using Affymetrix expression microarrays. A novel subgroup of putative resistant 
NSCLC cases to Pemetexed was identified and its distinct molecular attributes 
were bioinformatically studied.
Introduction
Presently, Pemetrexed is one of the most effective drugs for the treatment of 
non-small cell lung cancer (NSCLC). Pemetrexed is an anti-folate metabolite 
and targets multiple molecules essential in nucleotide biosynthesis (Chapter 
1. Fig. 2). It was established that it has possibly superior activity compared 
to commonly used agents in adenocarimoma (ADC) and large cell carcinoma 
(LCC) but is less effective in squamous cell carcinoma (SCC). In previous 
published studies, the effectiveness was related to the expression level of 
Thymidylate Synthase (TYMS). It was demonstrated that high expression of 
TYMS is associated with resistance to Pemetrexed in NSCLC (p = 0.006); 
furthermore a higher expression of TYMS is more often seen in SCC than 
ADC and LCC [1-3]. Based on those preclinical observations, Pemetrexed 
is approved as the first-line treatment in combination with other agents for 
advanced non-SCC NSCLC patients [2]. Its efficacy when used as a single 
agent for first-line treatment is under investigation.
 Among ADC and LCC patients, the response rate to Pemetrexed varies 
between 16 to 45%. Intriguingly, a significant number of ADC and LCC 
cases with high level of TYMS expression were observed, as determined by 
immunohistochemistry. Therefore, it indicates that to reach a higher CR/RR 
of Pemetrexed, it is vital to predict the response for individual patients by 
actually recruiting a substantial criterion, such as TYMS expression level, 
while histology-based stratification is proved insufficient in clinical practice.
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Genome-wide expression studies have revealed that NSCLC subgroups may 
be classified beyond classical histo-pathological criteria [4-7]. The clinical 
potential of such refined phenotyping of NSCLC tumors, however, has as yet 
not been fully explored.
 In this study, we show that ADC and LCC can be partitioned into novel 
subgroups based on global gene expression profiles. A subset of ADC and LCC 
were clustered in a novel group. Analysis of the expression level of TYMS 
and relevant genes indicates that tumors in this group are highly likely to be 
resistant to Pemetrexed therapy. The identification of this distinct subgroup of 
NSCLC suggests that biological characteristics assessed by gene expression 
profiling may aid in reliably stratifying patients in respect of Pemetrexed 
first-line therapy. Thus, we propose a clinically feasible approach to evaluate 
expression levels of TYMS and associated genes, in order to molecularly 
predict Pemetrexed efficacy in NSCLC patients.
Materials and Methods
NSCLC tumor smaples
Ninety-one resected tumor samples from NSCLC patients were collected at the 
Erasmus MC between 1992 and 2004. Tissues was collected and studied under 
an anonymous tissue protocol approved by the local medical ethical committee 
of the institution.
Histopathological analysis 
All tumor samples were independently reviewed by two pathologists. The 
dominant molecular characteristics of tumors were also verified by histology 
gene signatures established in Chapter 4. According to the molecular level 
classification, the cohort included 45 ADC, 27 SCC, and 19 LCC, including 
3 CAR classified as LCC and 1 as ADC. Patient and tumor characteristics are 
listed in Supplementary Table 1.
NSCLC cell lines 
Nine NSCLC cell lines within NCI-60 drug screen panel were transcriptionally 
profiled by Affymetrix U133 Plus 2.0 array (GSE8332). The expression of 
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relevant probe-sets of interest was directly retrieved from Gene Expression 
Omnibus (GEO) database (NCBI) with using a script written in MATLAB. 
The sensitivity of these NSCLC cell lines to Pemetrexed was tested in vitro 
using a standard MTT colorimetric assay via quantifying the amount of viable 
cancer cells [8].
Microarray data analysis
RNA from frozen tumor tissues was isolated and processed according to the 
standard protocol for Affymetrix U133 Plus 2.0 arrays. The details about 
microarray data processing and normalization are described in Chapter 4 
Supplementary Method.
Scoring formula using Internal Reference Genes (IRG)
The detailed predictive scheme methodology is described in Supplementary 
Materials and Methods. The scheme predicted tumor response utilizing the 
expression of TYMS, the major target of Pemetrexed, alone firstly, and then 
the expression of 3 targets, TYMS, DHFR, and GART. 
In the IRG scheme, the average expression level of 11 probe sets was used as 
the internal reference to determine the relative expression of Pemetrexed target 
genes. NSCLC patients were stratified in such a way that around 60% of cases 
were supposed to respond to Pemetrexed, while the remaining 40% of cases (~ 
40%) with higher expression levels of the signature genes were deemed to be 
non-responders.
Supervised analysis to identify resistance related genes 
An optimized gene signature characterizing high TYMS expression, and hence 
presumably resistance to Pemetrexed treatment, was obtained and validated 
with previously described bioinformatics approaches [9-11]. 
Tissue Microarray Analysis (TMA)/Immunohistochemistry
Tissue microarrays composed of 91 paraffin-embedded primary lung tumors 
from the same patients used for microarray analysis were constructed. Cores 
of 0.6 mm were punched from selected tumor areas from the donor block and 
placed in triplicate in an acceptor block. For immunohistochemistry, 5-µm 
sections were mounted onto slides and stored at room temperature until used. 
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Immunohistochemistry was performed using standard methods. 
Results
Six novel NSCLC subgroups 
Unsupervised clustering on expression profiles revealed six subclasses within 
91 NSCLC cases. The initial clustering was based on the similarity in global 
gene expression between the NSCLC samples and performed with 11,515 
probe sets. The distinct subgroups were also recognized when the number 
of probe sets was reduced to 4791, with the resulting six NSCLC subclasses 
presenting with the strongest similarities in gene-expression profiles within 
each subclass but dissimilar with other subclasses (Fig.1).
 The majority of tumor samples (89 out of 91) were clustered into 6 
groups. Two of these groups correlated well with classical histopathology 
classes: Group3 displayed a dominant SCC contribution, while the CAR 
samples (n = 4) were exclusively assigned to Group5. In contrast to these two 
groups, other groups did not show such a strong association with classical 
histology. They were to varying degrees composed of mixed histopathological 
NSCLC. ADC accounted for a major part of each of these groups, and most of 
LCC - large cell neuroendocrine carcinoma (LCNEC) were mingled with ADC 
in Group4 and Group6. Compared to Group1 and Group2, ADC in Group4 
and Group6 displayed gene expression patterns suggestive of neuroendocrine 
features. Regardless of histological consistency between Group1 and Group2, 
the NSCLCs in these two groups were distinguished by a low degree of cell 
differentiation and the expression of a large number of immune-related genes, 
respectively.
Gene expression-based prediction for response to Pemetrexed
The potential sensitivity of tumors to Pemetrexed treatment is thought to be 
positively correlated with the expression levels of enzymes in the nucleotide 
metabolic pathway [3, 12]. Expression of the relevant genes was extracted 
from the microarray data, and these were subsequently utilized as the basis of 
predictive schemes for Pemetrexed responsiveness.
Prediction in primary NSCLC1. 
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Fig. 1. Correlation view of 91 samples from patients with NSCLC. 
Pairwise correlations between any two samples are displayed. The colors of the cells 
represent Pearson’s correlation coefficient values, with deeper red indicating higher 
positive and deeper blue lower negative correlations. The red diagonal line displays 
the self-to-self comparison of each sample.
The expression of TYMS and/or DHFR, GART was compared to the average 
expression of internal reference genes. For each patient, if more than half of 
target gene representing probe sets had expression above the 60th percentile of 
that gene’s expression in the cohort, that patient was supposed to be resistant 
to Pemetrexed targeted therapy (NR); if none of probe sets had higher than the 
60th percentile expression, then responder to Pemetrexed was assigned (R); 
if just around half of probe sets had expression above the 60th, the medium 
sensitivity (M) was assigned to leave a margin between NR and R. According 
to the internal reference gene scheme, out of 91 NSCLC patients 35.2% were 
predicted as non-responders and 51.5% were predicted to be responders.
 The average relative expression value of TYMS from predicted non-
responders is 177.1 (95% CI: 143.2~210.9), 8.2-fold more compared to that 
in normal lungs; while predicted responders displayed a 2.2 fold change in 
relative expression value of TYMS compared to that in normal lungs. 
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Predicted resistance profile in relation to histology2.	
The predicted tumor resistance profile was studied in relation to the three 
major NSCLC subtypes, ADC, SCC and LCC. The histology was assigned 
using histology gene signatures identified in Chapter 4 which captured the 
most predominant molecular features of NSCLC.
Within these three major groups, LCC contained the highest relative 
expression of TYMS (192.0; 95% CI: 125.6~258.4), followed by SCC (86.6; 
95% CI: 73.0~100.1) and ADC (76.1; 95% CI: 58.5~93.7) (Fig. 2A and 
Supplementary Fig. 1). When expression of TYMS was compared to normal 
lung tissues, a significant difference was observed between each subtype of 
NSCLC and non-cancerous tissues, with 8.85-, 4-, and 3.5-fold differences in 
LCC, SCC, and ADC, respectively. Among subtypes of NSCLC, the difference 
in TYMS expression was statistically significant between LCC and other two 
subtypes, ADC and SCC; but not between ADC and SCC (Table 1).
ADC SCC LCC NL 
ADC - 0.398 0.002* 0 *
SCC - - 0.004* 0 *
LCC - - - 0 *
Table 1.The differences in TYMS expression between NSCLC and normal lung, or 
between any two NSCLC subtypes. Values in table are t-test P-values. 
The predicted resistance to Pemetrexed was correlated to 25% of ADC, 
33% of SCC, and 63% of LCC (Fig. 2B). By contrast, all non-cancerous 
tissues from same patients except for one were stratified as being sensitive to 
Pemetrexed, in accordance with the observation that the expression of TYMS 
is significantly higher in LCC, SCC, and ADC than in normal lung tissues.
A novel NSCLC group is associated with predicted Pemetrexed resis-3.	
tance
Since the number of predicted resistant cases (NR) in each histological 
subtype was not deviated enough to reliably make that subtype of NSCLC 
being contradictive to Pemetrexed therapy. We tried to correlate predicted
150
Chapter 5
B.
Fig. 2. Expression of TYMS and predicted non-responder in relation to histology
A. Expression of TYMS and distribution of high TYMS NSCLC in adenocarcinoma 
(ADC), squamous cell carcinoma (SCC), and large cell carcinoma (LCC) is compared 
to TYMS expression in normal lung (NL). B. the composition of internal reference 
gene scheme defined resistant NSCLC (NR), sensitive NSCLC (R), and medium 
sensitive NSCLC (M) in each NSCLC subtype.
Pemetrexed resistance to six novel NSCLC subgroups described in Fig. 1. 
It is noticed that a distinct resistance pattern of NSCLC to Pemetrexed was 
A. 
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recognizable by novel grouping of NSCLC
 In four out of the six groups, no more than 25% of the cases were 
defined as predicted non-responders, with percentages of 25%, 0%, 25% 
and 8.3% in Group1, Group2, Group5 and Group6 respectively. About 39% 
cases from Group3, which were characterized by SCC, were predicted as non-
responders. 
 In Group4, comprising large cell neuroendocrine carcinoma (LCNEU) 
and ADC with neuroendocrine features, a remarkable proportion of predicted 
non-responders was observed, 88.9% (16 out of 18) of cases in this group were 
gene expression-defined NR to Pemetrexed therapy (Fig. 3). 
Prediction based on the expression of all three targets
Next, the expression profiles of DHFR or GART were included to predict 
Pemetrexed resistant and sensitive NSCLCs. This resulted in a similar “non-
responder” distribution according to either classical histology or the novel 
groups as we observed with TYMS-only stratification. Similarly, Group4 was 
recognized by a high proportion of NR, with percentages ~60% and ~82% of 
cases predicted being resistant to Pemetrexed.
 When all three Pemetrexed target-encoding genes were utilized to 
equip the predictive scoring formulae, the resulting resistance pattern favored 
Group4 again (Supplementary Fig.2). 
 We conclude that the gene expression profile-based prediction shows 
that NSCLC cases falling into Group4 and around 40% of SCC are most likely 
to be resistant to Pemetrexed.
Distinct molecular characters of Pemetrexed resistant NSCLC-Group4
Three out of six distinct groups of NSCLC, Group4, Group5, and Group6 
comprised neuroendocrine tumors, including LCENC, CAR, as well as 
ordinary NSCLC with neuroendocrine differentiation, mainly ADC. Among 
them, Group4 and Group6 were histologically similar but varied in expression 
profiles. 
Neuroendocrine NSCLC and distinct features of Group41. 
Several neuroendocrine markers, including ASCL1, DDC, and MAST4 were 
expressed by tumors presenting evidence of neuroendocrine differentiation, 
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B.
 
Fig. 3. Expression of TYMS and predicted Pemetrexed response in relation to NSCLC 
novel groups. A. relative expression of TYMS and distribution of high TYMS 
NSCLC in each group compared to TYMS expression in normal lung tissue (NL). 
B. the composition of internal reference gene scheme defined resistant NSCLC (NR), 
sensitive NSCLC (R), and medium sensitive NSCLC (M) in each NSCLC novel 
subgroup.
such as LCNEC and a subset of ADC [6]. These genes were over-expressed 
by Group4 and Group6 NSCLC as well, indicating the presence of common 
neuroendocrine features among these groups regardless of their molecularly 
defined different histological characters. However, there was a 2- to 4-fold 
difference in expression of these markers between Group4 and Group6. 
Predicted Pemetrexed resistance in Group4 NSCLC2.	
A. 
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Pemetrexed is transported into and out cells by a class of membrane proteins, 
such as FOLR1, SLC19A1, and ATP-binding cassette family members. 
Moreover, Pemetrexed is metabolized by folylpolyglutamate synthetase 
in vivo. Besides high expression of TYMS, DHFR and GART, the aberrant 
expression of such related molecules may contribute to Pemetrexed resistance 
as well. Interstingly, we observed lower expression of FOLR1 in Group4 
NSCLC compared to other Groups. 
 We conclude that the novel Group4 of NSCLC has distinct molecular 
characteristics associated with predicted drug sensitivity.
Proposed Pemetrexed resistance signature
Predicted NSCLC resistance was characterized by 346 genes1. 
A set of 346/426 genes/probe sets characterizing predicted Pemetrexed 
resistance was identified using supervised analysis as described in Chapter 
4. The bioinformatics analysis revealed that cell cycle and cell proliferation 
genes, pyrimidine and purine metabolism, as well as folate biosynthesis were 
enriched in resistance signature (Supplementary Table 2).
 SOX2 and SOX4 are among the up-regulated genes, and surfactant 
genes are down-regulated in predicted non-responders. Interestingly, SOX7, 
a marker for squamous cell differentiation, was also down-regulated among 
patients in non-responders. Two solute carriers were also down-regulated 
genes, SLC16A4 and SLC46A3. Hereinto, SLC46A3 is from the same family 
as SLC46A1 which is responsible for the folate transporter in vivo at low pH 
level. By contrast, DNA damage repair associated genes, attributing to multi-
drug resistance, were found over-expressed in NRs, including TOP2A, PRIM1, 
and RFCs. Among resistance signature genes, a large number of cell cycle 
regulatory genes were found, including cyclin A2, B1, E1 and E2; CDC2, 
CDC6, CDC7, CDC20, and CDC25; checkpoint kinase CHEK1, and related 
PLK1, PLK4; proliferation or mitosis related genes like E2Fs, GTSE1, KIFs, 
MCMs, and IGFBP2; cell growth and invasion related genes MMP19; as well 
as known oncogenes and suppressor genes MYB, NBL1, RAS genes.
 A subset of genes, represented by 25 probe sets, optimally performed in 
predicting Pemetrexed resistance [10, 11]. 
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Validation of the putative Pemetrexed resistance signature by NSCLC 2. 
cell lines
The expression of resistance associated genes identified with primary NSCLC 
cohort was measured in transcriptionally profiled NSCLC cell lines (GSE8332). 
The performance of this signature was evaluated by comparing the prediction 
for cell line reaction to Pemetrexed to actual observations from drug sensitivity 
assays [8] (Fig. 4). The minimized prediction signature was achieved with a 
correct prediction of sensitivity to Pemetrexed in 94% (17 out of 18) of the 
cell lines. We note that resistant cell lines were all correctly predicted; the 
sensitivity of predicting resistance is 100%, with a corresponding specificity 
91.7%.
Comparison of non-responder classifiers to other signatures
The putative non-responder biomarker genes were compared to onco-
pathway signatures to further explore the role of these genes in oncogenesis 
(Supplementary Table 3) [13]. We noticed that the E2F3/G1S regulatory 
pathway was over-represented by the biomarker genes, followed by the SRC, 
P53, and RAS pathways. 
 The comparisons were also performed between putative non-responder 
biomarkers and other gene signatures developed in Chapter 4. The biggest 
overlap was found with novel Group4 signature (Supplementary Table 3).
Validation of TYMS expression in NSCLC
To validate expression of TYMS and other relevant genes measured on 
microarray, quantitative polymerase chain reaction (qPCR) was performed. 
Pearson’s correlation coefficient was used to measure the consistency in relative 
expression of tested genes between two assays (Supplementary Table 4).
 TYMS protein staining was graded from 0 to 3 corresponding to 
no staining, plus 1 to 3 staining. The mRNA expression level measured on 
microarray for each staining category was shown in Fig. 5. Since only one 
sample had staining scaled with 3 plus, it was combined with other plus 2 
staining NSCLCs.
 The average expression of TYMS of Grade2 was 3.73-fold and 2.52-
fold higher than Grade0 and Grade1 respectively (P_value = 1.11E-07). The
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Fig. 4. A. The correlation of cisplatin response and Pemetrexed response [8]. 
B. Predicted sensitivity to Pemetrexed for NSCLC cell lines in comparison to 
experimentally established sensitivity.
correlation between staining intensity and predicted Pemetrexed resistance is 
shown in Figure 5 and Supplementary Figure 4. Over 85% NSCLC with Grade2 
staining were predicted resistant to Pemetrexed based on mRNA expression 
of TYMS. Conversely, less than 30% of NSCLC with Grade1 staining were 
predicted non-responder. The expression difference of TYMS in non-responder 
between staining Grade0 and Grade1 was not statistically significant (P-value 
= 0.993), however, TYMS presented a significant higher expression in Grade2 
compared to either Grade0 or Grade1 with p-values of 0.067 and 0.048.
Discussion
Chemotherapy acts as a two-edged sword in cancer therapy. It provides an 
alternative to surgical removal to kill cancer cells and prevents disease 
progression on one side. On the other side, chemotherapy introduces a range
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Fig. 5. The correlation of TYMS protein staining and mRNA expression. 
Protein staining on TMA was graded from 0 to 2 (StainingS), mRNA expression 
measured on expression microarray was represented as mean of two probe sets for 
TYMS (AverageTS).The predicted response to Pemetrexed was illustrated by non-
responder (NR), responder (R), and medium sensitivity (M).
of side-effects affecting normal cells in the body, leading to clinical 
complications, such as nausea, anemia, multiple organ toxicity, myelo-
suppression, and secondary neoplasms. Contradictive roles of chemotherapy 
require tailored regimens for individual patients, obtaining maximal effect 
while drug-related toxicity remaining at a tolerable grade. Currently, the 
application of chemotherapy is based on histology, resulting in no more of a 
16% of response for common chemotherapeutic agents and 40% for combined 
regimens, at the same time a 5-year survival kept low [14]. 
 The fact that cancer patients with similar pathological features response 
dramatically different to the same therapeutic agent indicates that histology 
alone is insufficient to determine tumor response to chemotherapy. Thus, there 
is need to improve the stratification of cancer patients and predict clinical 
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outcome following a particular treatment. 
 Pemetrexed is a promising anti-metabolite agent for the treatment of 
NSCLC, which produces comparable anticancer-activity to other conventional 
agents, but drug-related toxicity is much milder [1]. Currently, the administration 
of Pemetrexed is limited to ADC and LCC cases, since preclinical studies 
demonstrated no apparent benefits for SCC patients. 
 In this study, however, we find that the TYMS expression-based 
prediction of NSCLC response to Pemetrexed does not correlate well with 
the classical histological subtypes. Using the genome-wide expression data, 
we identified a novel subgroup of NSCLC with both neuroendocrine features 
and altered tyrosine metabolism that is predicted to be resistant to Pemetrexed 
treatment (Supplementary Fig. 3). In contrast, other NSCLCs, including ADC 
and LCC in Group1 and Group6 in particular, were identified as candidates 
for Pemetrexed treatment as they were predicted to respond favourably to the 
treatment. Remarkably, around of 60% SCC in our cohort were predicted to 
be sensitive to Pemetrexed therapy. This suggests that Pemetrexed may be 
an effective chemotherapeutic agent for this subset of patients. Similarly, our 
analysis suggests that CAR in Group5 is another subset of tumours that might 
benefit from Pemetrexed therapy. Although the activity of this agent in patients 
with this type of tumor needs to be evaluated further.
 In summary, NSCLC cases predicted to be resistant to Pemetrexed 
include:
ADCs, with evidence of neuroendocrine differentiation and in associa-•	
tion with aberrant tyrosine metabolism, in Group4;
LCNEC classified into Group4;•	
A subset of SCC, around 40%;•	
Validation of the predicted Pemetrexed non-responder gene signature
The role of TYMS expression in the efficacy of Pemetrexed therapy has been 
established by several studies [3, 8, 12, 15]. We stratified NSCLC patients 
into different response groups using TYMS expression levels extracted from 
microarray data, and extended these observations to develop a Pemetrexed 
resistance gene signature. The performance of this resistance signature 
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was evaluated with NSCLC cell lines whose sensitivity to Pemetrexed was 
previously determined [8].
 This non-responder gene signature accurately predicted Pemetrexed 
sensitivity of the NSCLC cell lines. Unfortunately, it is currently not feasible 
to use patient samples for validation of the performance of the non-responder 
gene signature, due to several factors. 
Lack of availability of tumor material before treatment to identify 1.) 
determinant genes for Pemetrexed response. The postoperation survival 
rate of NSCLC remains low, even among stage I patients. Most of 
patients deceased within 2 years of the operation, due to the progression 
of NSCLC or accompanying systematic complications. It is extremely 
rare to have the collection of primary and the second surgery-resections 
from the same patients, not mention to patients received Pemetrexed 
treatment.
Combination with cisplatin or following other agents makes it difficult 2.)	
to assess the role of Pemetrexed alone. Pemetrexed is approved as 
second-line treatment of NSCLC, or first line treatment of NSCLC 
in combination with cisplatin. According to previous studies [16], 
chemotherapy can induce a global change of gene expression. Therefore 
the independent effect introduced by Pemetrexed is hard to monitored 
using clinical patient materials. Although few clinical trials where 
Pemetrexed was administrated as the single agent of first line therapy 
for NSCLC patients are ongoing, the availability of corresponding 
tumor samples is still quite limited.
Evaluating TYMS expression level by IHC
TYMS staining was performed at two different antibody titers, 1:10 and 1:50. 
As shown in Supplementary Fig. 4, strong staining/TMA high grade NSCLCs 
are predominantly associated with non-responder predicted on the basis of 
mRNA expression levels. In weak staining/low grade NSCLCs, however, 
resistant cases accounted for 21 to 29% of whole cases.
 The similar scale of staining between Grade0/1 non-responder and 
responder was postulated to result from unspecific staining of TYMS. This 
Expression profiling based prediction of Chemotherapy response
159
assumption is supported by staining with a lower antibody titer (1:50). 
Supplementary Figure 4 shows TYMS staining with more diluted TYMS 
antibody, and scaled identically with low titer TMA. Predicted non-responders 
are still predominant in TMA Grade2 population of similar size as the previous 
one. By contrast with TMA at titer 1:10, only one non-responder is found in low 
titer Grade1 NSCLCs (1 out of 8, 12.5%), with unspecific staining eliminated to 
great extent. Higher diluted antibody on the other hand failed to detect relatively 
low expression of TYMS, with 80% of the cases showing no TYMS protein 
expression and scaled as Grade0. The results illustrate the technical difficulties 
in determining patients’ TYMS levels through routine immunohistochemistry. 
Herewith, we provide candidate molecules, such as DEPDC1, as surrogate 
markers whose expression levels in NSCLC should reflect TYMS expression 
levels, while allowing faithful measurement in routine clinical practice.
Gene expression profiles may guide the choice of chemotherapy regimens
We suggest that molecular profiles of individual NSCLC tumors may be used to 
predict patient response to Pemetrexed chemotherapy (Fig 6). Our observations 
indicate that a subset of NSCLC, independent of histology, should be contra-
indicated for Pemetrexed as therapeutic agent. Since a reverse correlation 
between Pemetrexed and Cisplatin sensitivity that has been observed in ovarian 
cancer patients [8], Cisplatin could be used in those cases. Furthermore, the 
efficacy of Pemetrexed in patients with low-TYMS SCC deserves further 
exploration. Our data suggest that a significant number of SCC patients may 
benefit from Pemetrexed treatment.
 To implement in clinical practice, we propose a set of biomarkers for 
IHC which overcome the poor reliability of IHC staining to evaluate TYMS 
expression levels. We show that IHC results obtained with DEPDC1 or other 
antibodies correlates much better with the TYMS expression levels determined 
by microarray and Q-PCR. Thus, use of these novel markers may aid in deciding 
to select the treatment regime for individual NSCLC patients.
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Fig. 6. Study scheme and hypothesized clinical application of biomarker-based 
prediction for Pemetrexed non-responders
References
1. Esteban, E., M. Casillas, and A. Cassinello, Pemetrexed in first-line treatment of non-
small cell lung cancer. Cancer Treat Rev, 2009. 35(4): p. 364-73.
2. Longo-Sorbello, G.S., et al., Role of pemetrexed in non-small cell lung cancer. Cancer 
Invest, 2007. 25(1): p. 59-66.
3. Travis, W.D., et al., Reproducibility of neuroendocrine lung tumor classification. 
Hum Pathol, 1998. 29(3): p. 272-9.
4. Takeuchi, T., et al., Expression profile-defined classification of lung adenocarcinoma 
shows close relationship with underlying major genetic changes and clinicopathologic 
behaviors. J Clin Oncol, 2006. 24(11): p. 1679-88.
5. Bhattacharjee, A., et al., Classification of human lung carcinomas by mRNA expression 
profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A, 
2001. 98(24): p. 13790-5.
6. Anbazhagan, R., et al., Classification of small cell lung cancer and pulmonary 
carcinoid by gene expression profiles. Cancer Res, 1999. 59(20): p. 5119-22.
7. Tusher, V.G., R. Tibshirani, and G. Chu, Significance analysis of microarrays applied 
to the ionizing radiation response. Proc Natl Acad Sci U S A, 2001. 98(9): p. 5116-
Methodology	for	
predicting	NR/R
Underlying	feature	of	NR	
(Supp.	Table	1	&	2)
Chemo-response	according	
to	NSCLC	histology	(Fig.	2)
Chemo-response	according	
to	novel	NSCLC	classification	
(Fig.	3)
Indication	for	new	
chemotherapy	strategy
Validation	Resistance-
signature 
(Fig.	4	&	5)
Strategy of 
diagnose	NR	in	
clinics	(Fig.	5)
Biological	interpretation	
of	putative	Resistance	
signature (Supp.	Fig.	3)
Expression profiling based prediction of Chemotherapy response
161
21.
8. Tibshirani, R., et al., Diagnosis of multiple cancer types by shrunken centroids of 
gene expression. Proc Natl Acad Sci U S A, 2002. 99(10): p. 6567-72.
9. Golub, T., et al., Molecular classification of cancer: class discovery and class 
prediction by gene expression monitoring. Science, 1999. 286: p. 531-536.
10. Hsu, D.S., et al., Pharmacogenomic strategies provide a rational approach to the 
treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol, 2007. 
25(28): p. 4350-7.
11. Meier, P. and E. Kaplan, Nonparametric estimation from incomplete observations. J 
Am Stat Assoc, 1958. 158: p. 457-481.
12. Bepler, G., et al., Clinical efficacy and predictive molecular markers of neoadjuvant 
gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol, 
2008. 3(10): p. 1112-8.
13. Giovannetti, E., et al., Cellular and pharmacogenetics foundation of synergistic 
interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer 
cells. Mol Pharmacol, 2005. 68(1): p. 110-8.
14. Bild, A.H., et al., Oncogenic pathway signatures in human cancers as a guide to 
targeted therapies. Nature, 2006. 439(7074): p. 353-7.
15. Rosell, R., et al., The biology of non-small-cell lung cancer: identifying new targets 
for rational therapy. Lung Cancer, 2004. 46(2): p. 135-48.
16. Hanauske, A.R., et al., In vitro chemosensitivity of freshly explanted tumor cells to 
pemetrexed is correlated with target gene expression. Invest New Drugs, 2007. 25(5): 
p. 417-23.
17. Buchholz, T.A., et al., Global gene expression changes during neoadjuvant 
chemotherapy for human breast cancer. Cancer J, 2002. 8(6): p. 461-8.
162
Chapter 5
Supplementary Material and Method
Microarray data processing and normalization
RMA normalization Microarray data was normalized by RMA algorithm. 
RMA (Robust Multi-Array average) is an integrated algorithm comprising 
background adjustment, quantile normalization, and expression summarization 
by median polish [17]. The intensities of mismatch probes were entirely ignored 
due to their spurious estimation of non-specific binding. The intensities were 
background-corrected in such a way that all corrected values must be positive. 
The RMA algorithm utilized quantile normalization in which the signal value 
of individual probes was substituted by the average of all probes with the same 
rank of intensity on each chip/array. Finally Tukey’s median polish algorithm 
was used to obtain the estimates of expression for normalized probe intensities. 
Intensities of probe sets lower than 30 were reset to 30.
Probe sets filtering Probe sets were involved in further analysis only if their 
expression levels deviated from the overall mean in at least one array by a 
minimum factor of 2.5, because the remaining data were unlikely to be 
informative. The result was that 43,160 probe sets were eliminated, and 11,515 
probe sets remained for further analysis.
Unsupervised clustering and Novel grouping of NSCLC
Omniviz software (Omniviz, Maynard, MA) was used to measure the 
similarities in expression profiles among samples based on 11,515 selected 
probe sets (Chapter 4 Supplementary material). The samples were ordered so 
that those sharing strong similarities were arranged together into clusters. The 
clusters and the individual samples within the clusters were sorted in such 
a manner that the more similar subjects were more closely positioned in the 
visualization matrix. Six distinct NSCLC clusters were identified by gene 
expression profiles, as described in Chapter 4.
Scoring formula elaborating
The expression of genes encoding Pemetrexed targets measured by microarray 
was employed to classify NSCLC to different response groups. All schemes 
predicted tumor response utilizing the expression of TYMS, the major target 
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of Pemetrexed, alone firstly, and then the expression of all 3 targets, TYMS, 
DHFR, and GART. 
Internal Reference Genes (IRG)1. 
To be less prone to cohort-inherent and any analysis-derived variability, the 
methodology was adjusted to be individually determinant, the expression level 
of TYMS genes being scaled in comparison with other genes from the same 
tumor instead of with the expression of same genes across all tumors in the 
cohort.
 To define internal reference probes/genes, we firstly selected top 100 
probe sets which showed a constant expression under various conditions. The 
constant expression of those probe sets was confirmed by an independent data 
set [18], which contained a similar number of NSCLC samples (n = 96). To 
be applicable in future for different platforms or different generations of the 
same platform, we checked the presence of these probe sets on U133 set of 
Affymetrix chips. The average expression of 11 probe-sets was used as the 
internal reference to determine the relative expression of genes encoding 
Pemetrexed targets. 
 The percentile rank-based definition2.	
Responder: none of counted probe-sets/genes showed an expression above the 
60th percentile of that population; in case all 3 targets were used, no more than 
3 counted probe-sets had expression intensity above the 60th percentile of the 
population studied.
 Non-Responder: at least 2 out of 3 probe-sets/genes presented an 
expression higher than 60% of studied population; Or 6 out of 14 in cases 
where all 3 targets were counted.
Supervised analysis to identified Pemetrexed resistance associated genes
Gene profiling with respect to predicted sensitivity to Pemetrexed was 
performed by using Significance Analysis of Microarray (SAM). SAM 
discovered differentially expressed genes between two classes [9], predicted 
non-responders and responders. 
 The obtained signatures were subjected to identify subgroups of genes 
that maintain the capacity of the complete signatures in distinguishing dif-
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ferent groups maximally [10]. The performance of optimized signatures was 
validated by “leave-one-out” cross validation [11].
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Supplementary Table 1. Clinical characteristics of NSCLC patient cohort
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Supplementary Table 2. Bioinformatics analysis revealed over-represented 
biological functions by non-responder classifiers
KEGG-pathways Biocarta-pathways I n g e n u i t y - c a n o n i c a l 
pathways 
Cell cycle Role of Ran in mitotic 
spindle regulation
Cell cycle: G2/M regulation
Pyrimidine 
metabolism 
Cyclins and Cell cycle 
regulation 
Role of BRCA1 in DNA 
damage response 
P53 signaling 
pathway 
Cell cycle: G2/M & 
G1/S check point
Pyrimidine Metabolism 
DNA polymerase CDK regulation of 
DNA replication 
Cell Cycle: G1/S regulation 
Purine metabolism AKAP95 role in mitosis 
and chromosome 
dynamics 
Purine metabolism
Folate biosynthesis Regulation of p27 
phosphorylation during 
cell cycle progression 
Folate biosynthesis 
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Supplementary Table 3. Comparisons of resistance classifiers to other 
signatures. Numbers in the table are overlapped probesets between two 
signatures.
                                                                           Resistance Signature_524   
Histology Signature_518 42 (8 : ADCSCC; 34 : LCC) 8.1% 
LCC Signature_189 34 18% 
Histology Signature_75 0 
Tumor Signature_187 45 24.1% 
Tumor Signature_5 2 40.0% 
Group Signature_964 51 (44 : G4) 5.3%
Group4 Signature_139 44 31.7% 
Survival Signature_17 0 
Duke_Ras signature_209 1 0.5%
Duke_Src signature_31 3 9.7% 
Duke_Myc signature_133 8 6.0%
Duke_E2F3 signature_164 25 15.2% 
Duke_bCatenin signature_38 0 
KEGG_EGFR pathway_29 0 
KEGG_RAS pathway_143 10 7.0% 
KEGG_P53 pathway_79 7 8.9% 
KEGG_G1S pathway_30 9 30.0%
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Supplementary Table 4. The consistency of gene expression between 
microarray and qPCR assay in form of Pearson Correlation coefficient 
(CC) 
qPCR microarray CC
  
TYMS 1554696_s_at 0.69
 202589_at 0.70
  
DHFR 202532_s_at 0.87
 202534_x_at 0.84
  
GART 217445_s_at 0.16
 230097_at 0.04
  
 average of 2 Probe-sets
TYMS TYMS 0.72
  
DHFR DHFR 0.85
  
GART GART 0.05
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Supplementary Fig. 1. Relative expression of TYMS and distribution of high 
TYMS tumor in subtypes of NSCLC, adenocarcinoma (ADC), squamous cell 
carcinoma (SCC), and large cell carcinoma (LCC).
Expression profiling based prediction of Chemotherapy response
171
Supplementary Fig. 2. Prediction of NSCLC sensitivity to Pemetrexed using 
expression of DHFR, GART, or all three targets of Pemetrexed, in correlation 
to NSCLC novel subgroups. NR, resistant NSCLC; R, sensitive NSCLC; M, 
medium sensitive NSCLC.
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Supplementary Fig. 3. Pyrimidine metabolic pathway (upper) and EGFR 
signaling pathway (lower) deregulated in a subgroup of NSCLC, which is 
characterized by putative resistance to Pemetrexed therapy.
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Supplementary Fig. 4. TYMS protein staining on TMA was graded from 0 to 
2 (StaingS). The TMA staining scores at two different titers (A, 1:10; B, 1:50) 
are shown in relation to TYMS mRNA expression on microarray.
StainingS
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Discussion
Pharmacogenomics: toward personalized chemotherapy1) 
In Chapter 5, we discriminated a subset of NSCLC with respect to putative 
Pemetrexed resistance from the rest of NSCLC. Instead of common histological 
characters, this subset of NSCLC is distinct in altered folate-related pathway 
and tyrosine metabolism. The unique expression pattern of enzymes directly 
targeted by Pemetrexed and other relevant genes, such as  transporter molecules, 
not only provided a molecular rationale to predict the outcome of Pemetrexed 
therapy, but also postulated additional targets for other  therapeutic agents 
that might act in combination with Pemetrexed to further improve RR and 
prognosis for specific subsets of NSCLC patients.
 Furthermore, we propose a scheme for the design of personalized 
therapy on the basis of molecular profiling of individual tumors. The expression 
measurement of specific genes, such as TYMS, combined with integrated global 
expression profiling classified NSCLCs into novel groups beyond conventional 
histopathological characteristics. Tumors of different groups were aggregated 
by their similar molecular behaviors rather than morphological hallmarks. 
Accordingly, different therapeutic regimens were proposed for different 
subgroups of NSCLC. Thus, Group1, Group2 and Group5 identified in this 
study, regardless of their histology, may receive Pemetrexed-based first-line 
treatment. For Group4 NSCLC, with strong contra-indication for Pemetrexed 
therapy and EGFR-TKI/antibody, standard platinum-based regimens might 
be the best option. SCC is a NSCLC group distinct in pathogenesis and also 
carcinogenesis. The stratification of SCC with respect of chemoresistance by 
TYMS and ABCC1 expression in this study suggests that the use of Pemetrexed 
to treat SCC patients should be re-evaluated.
 As suggested by our study, new methodologies should be developed 
that enable division of NSCLC into molecularly characterized subgroups. 
These subgroups are anticipated to guide the clinical algorithms used to treat 
NSCLC patients in the future.
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Experimental design an interpretation of analysis results2)	
Different experimental set-ups, such as cell type composition of patient 
samples, attribute to inconsistent results among studies addressing the same 
questions. For instance, if we see that outcome signatures make predictions 
beyond histology subtypes in the original data set, it is conceivable that genes 
associated with prognosis are still histology-related. When these signatures are 
applied to other sample sets with different histology composition, they do not 
necessarily reflect hazard of recurrence or chance of survival.
 In Chapter 4, we validated published prognostic signatures with our 
NSCLC Cohort and the Duke NSCLC Cohort. It is noticeable that a signature 
developed with ADC samples remained histology-dependent, and failed to 
stratify mixed NSCLC samples from both cohorts. It performed satisfactorily, 
however, on the ADC samples from these cohorts which were assigned by the 
histology gene signature developed also in this study. Clearly, it is essential to 
test the current prognostic classifiers further with more independent datasets 
containing a broad histo-pathological spectrum of NSCLC cases.
Gene signatures versus conventional factors3)	
Expression profiling can provide improved tumor classification and outcome 
prediction compared to traditional clinical and histo-pathological assessments. 
However, gene expression profiles to a great extent reproduce histopathologcal 
characteristics. Considering this, it is likely that the predictions derived from 
gene signatures should also take conventional factors into account (smoking 
history, tumor stage, grade, size, and cell type). 
 It remains challenging to determine on which aspects expression 
profiling should focus. For questions which could be answered already with 
high accuracy by conventional examinations, with gene-based classifiers or 
predictors merely providing the same information, there is no need to perform 
relatively expensive microarray analysis. Expression profiling is better suited 
to answer questions that challenge conventional histo-pathological methods, 
such as identifying markers that provide prediction values beyond conventional 
factors or molecular predictors that explain variable clinical outcomes among 
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patients with similar histo-pathological features. 
Pathway analysis may overcome some of the inherent shortfalls of gene 4) 
expression analysis
Like many other methodologies, gene expression profiling is a snapshot 
of a tissue at a certain time point and within a certain in vivo environment. 
Current bioinformatics algorithms favor genes with high expression or highly 
differential expression. As a result, genes associated with obvious phenotypes 
or highly expressed when the tissue is isolated may overwhelm those genes 
with low-level expression or associated with subtle expression differences. 
Such genes might be relevant to specific clinical questions. 
 It easily explained why cell cycle- and cell-type associated genes are 
predominantly found in phenotypic comparisons, while metastasis-associated 
genes are rarely picked out. Furthermore, metastasis genes are more likely 
recruited as determinants for cell differentiation since fast growth and early 
metastasis are hallmarks of poorly differentiated tumors. Therefore, such 
genes usually appear in histologicy signatures and are not easily associated 
with metastasis. 
 Knowledge-based analyses, such as gene set enrichment analysis, make 
it possible to gain further insight into genes that do not show dramatic changes 
under different conditions. This type of approach is based on prior biological 
knowledge, and focuses on predefined gene sets, such as genes involved in a 
given biochemical pathway, so that the analysis is performed under the guidance 
of biological relevance. By applying this methodology, profiling analyses are 
less prone to magnitude-derived bias. 
Lack of overlap between different tumor/survival signatures 5)	
The lack of overlap between different signatures can be explained by the dif-
ferences between patient populations with respect to ethnic background, tumor 
heterogeneity, and environmental influence.
 Other possible explanations include the different bioinformatics ap-
proaches utilized by different studies which may also attribute to this diver-
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gence. For instance, validation of our prognostic signature with the Duke Co-
hort failed when the microarray data was processed and normalized together 
with those from the EMC cohort. In contrast, the signature was able to stratify 
NSCLC patient outcome when the Duke Cohort was processed independent of 
the EMC Cohort. 
 In another effort in this study to validate the prognostic signature, the 
raw microarray files (.CEL) of a Korean Cohort were not accessible. The nor-
malized microarray data deposited in the GEO database was downloaded and 
directly fitted to our prognostic model. The normalization utilized for the data 
provided was GCRMA - a modified RMA with MM signals included in the 
calculation. This leads to much more information retained at probe-set level 
compared to RMA normalized data used in our study. Thus, such variations in 
data processing obscure relevant information and obstruct comparative analy-
ses. 
 There are other technical issues responsible for inconsistent results 
between different studies, such as microarray platforms used and sample-
processing techniques. To make microarray results comparable across 
independent studies, it is therefore still needed to further develop standardized 
experimental protocols and more robust data analysis pipelines.
Microarray studies are prone to different bioinformatics approaches6) 
Except for underling biological variations among microarray experiment 
sets, microarray data sets might differ from each other as a result of data pre-
processing, normalization, and statistic analysis.
 Although a large number of publicly accessible analytic tools for 
microarray data exist to date, a ‘gold standard’ for dealing with microarray 
data is still lacking. Most microarray experiments follow a step-wise analysis, 
including data processing, class comparison, class prediction, clustering, and 
pathway analysis. Each single step, however, can be accomplished by diverse 
algorithms, software, and statistical analyses. Even for datasets undergoing 
comparable processing and analytical steps, the different adjustments on 
statistical significance and selection criteria will contribute to different outcome 
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gene lists.
 There are no definitive answers to the best procedures that should be 
followed to address these issues. Instead, depending on the specific questions 
addressed in a study, some algorithms or analyses will be superior to others. 
 In this study, the sample dataset was subjected to SAM analyses 
integrated in different software to answer the same questions. The best overlap 
between two generated gene lists was 70%. Another example, in a predictive 
classifying analysis the optimized gene set generated by PAM is only half of 
the gene set produced by correlation analysis followed by a regression model. 
The reason is that the PAM algorithm excludes genes negatively correlated to 
a phenotype in building a predictive expression matrix.
Meta-analysis of expression microarray data7)	
Meta-analysis (analysis of the analyses) has superiority in increasing sample 
size and thus statistical power, enabling generalization of the conclusions 
drawn. However, cross-study analysis of microarray data is complicated by 
variations in the types of array platform, the format of raw data, the number of 
genes studied, the design and nomenclature of representative probes, and the 
analytical methodologies. It is not uncommon that the predictor or signature 
genes identified in original studies performed poorly when applied to datasets 
independently collected at other institutes. Sun et al. identified two sets of 
prognostic genes for ADC and SCC respectively by using gene expression 
profiling [1]. However, they did not perform satisfactorily in two independent 
patient cohorts. Some studies reselected outcome classifiers from published 
microarray analyses. The classifier genes were validated by RT-PCR on 
independent samples, but their predictive abilities were not great [2-4]. Such 
discrepancies cannot be totally removed by simple data re-processing and re-
normalization.
 Many algorithms and statistical methods have been developed to solve 
this issue. However, none of these performs sufficiently well to be used as a 
standard for the inter-group/-platform studies aimed at integrating multiple array 
datasets. Sohal et al. showed that when unsupervised clustering was performed 
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using multiple microarray datasets, samples were grouped primarily based on 
the data sources or microarray platforms instead of biological status. However, 
the gene expression signature defining a certain phenotype could distinguish 
different biological tissues even in the presence of study-specific bias, as 
described in Chapter 4 (Supplementary Fig.1), indicating that the differential 
biological processes represented by selected genes was still retained despite 
the systematic inter-study variability [5].
Systematically studying NSCLC carcinogenesis 8) 
Gene expression profiling produces a snapshot of global expression at a certain 
time point, however, it is unable to decipher the regulatory mechanisms and 
regulatory networks as underlying gene expression determinants. To answer 
such questions, it is necessary to integrate high-throughput data from different 
levels, including genomic profiling such as single nucleotide polymorphisms 
(SNP), transcriptomics, and DNA methylation by high-throughput sequencing, 
and proteomics. 
 Technically similar to expression microarray, Affymetrix SNP arrays 
probes up to 906,600 SNPs and 946,000 copy number variation (CNVs). It 
is able to get insight into the genotype of cancer cells, revealing common or 
rare SNPs, and chromosomal abnormalities such as gains or losses. A study 
published recently linked a small number of CNV and SNPs, including well-
known 3q and SNPs located in STK39, with overall survival of early stage 
NSCLC, and the association was retained in two validation cohorts [6]. By 
integrating SNP array data with gene expression profiles, the effect of DNA 
changes on mRNA transcription can be assessed and it might provide more 
reliable predictors for cancer patient outcome. Under this hypothesis, Broet 
and his colleagues developed a methodology to integrate CGH data and 
expression profiles. The application of this methodology identified around 100 
genes located within 4 chromosomal regions. The predictive performance of 
those integrated markers for the risk of early relapse was more robust than the 
performance of either genomic or transcriptomic predictors alone in NSCLC 
[7]. 
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 A direct assay to study the interaction of regulatory factors and 
mRNA transcription is more and more widely used, that is Chromatin 
immunoprecipitation (ChIP)-based high-throughput technique. This technique 
makes use of the interaction of protein-DNA to assess the binding (sites) 
of particular transcription factors to DNA. ChIP technique is enhanced by 
combining with microarray technology, termed as ChIP-on-chip and allowing 
the identification of genome-wide binding sites for a certain protein. Alternative 
application of ChIP-on-chip is to study the role of promoter methylation in 
carcinogenesis. In this case, DNA regions containing methylated cytosine 
residues are recognized and precipitated by antibodies specific to meC. The 
resulting DNA fragments are poured over an array, which is spotted with a 
large number of probes tiling promoter regions – 10 kb adjacent to transcription 
start sites taking Affymetrix chip as an example. By comparing to the output 
fragments from normal tissues, the cancer specific methylation within 
promoter CpG islands can be portrayed. A further development of ChIP-based 
technique is termed as ChIP-seq, the combination of ChIP and high-throughput 
sequencing. A prominent improvement of ChIP-seq compared to ChIP-on-chip 
is the unbiased whole-genome identification of protein-DNA interactions or 
methylated CpG islands. By contrast with ChIP-on-chip, sequencing requires 
no hybridization arrays and therefore is not restricted by the probes spotted on 
the array. All precipitated DNA fragments are sequenced followed by alignment 
to the whole-genome sequence. Using ChIP-seq analyses in conjunction with 
whole-genome expression profiling is a promising methodology to get a 
closer insight into transcription factor networks and epigenetic modifications 
underlying biological processes and diseases; to understand how epigenetic 
abnormalities trigger and promote carcinogenesis through regulating gene 
expression; and to discover the most reliable biomarkers for early detection 
and prognosis prediction of cancer.
 Other levels of high-throughput analyses potentially to be integrated 
with expression profiles include exon or whole-transcript arrays targeting all 
alternative splicing variants of a gene; mciroRNA profiling to reveal mechanisms 
of mRNA processing and translation regulation; and mass-spectrometry to 
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assess active complexes at protein level in cancer cells.
 The most challenging task currently is how to combine massive 
experimental data from different levels and to single out biologically relevant 
information in order to interpret cancer-associated molecular profiles at systems 
level. To solve these problems, intensive knowledge of biology, oncology, 
bioinformatics, database, mathematics, statistics, are required and need to be 
used in combined approaches.
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Summary
Lung cancer is the most common cause of cancer death worldwide. The difficulty 
to detect lung cancer at early stages with current techniques is believed to be 
a major reason for this high mortality rate. Another important factor is that 
patients with advanced NSCLC respond highly variable to the same treatment. 
To improve NSCLC-related clinical outcome, it is important to identify highly 
specific markers for early diagnosis, to classify tumors with different biological 
behaviors, and to develop accurate predictive models for disease progression. 
It is also highly desirable to understand the molecular mechanisms underlying 
chemotherapy resistance.
 We aimed to address some of these issues by gene expression profiling 
of tumors and adjacent non-cancerous lung tissues.
 In Chapter 1, a general introduction to NSCLC is given. Relevant 
information includes lung cancer epidemiology, tumor histology, and clinical 
pathology. Subsequently, prognosis and present therapeutic regimens are 
discussed. From this chapter, the reader will have an overview of diagnosis 
and classification of lung cancer in clinical practice; the expected outcome of 
NSCLC, and which possible treatments the patients could receive. 
 Chapter 2 discusses the variety of factors contributing to lung 
carcinogenesis. The acquired abnormalities drive respiratory epithelia to 
deviate from normal cell growth and differentiation fate, leading to initiation of 
cancer cell transformation. Critical alterations discussed in this chapter include 
genetic instability at Chr. 3p and Chr. 9p, and aberrant expression of oncogenes 
(e.g. RAS, EGFR) and tumor suppressor (e.g. TP53, RB).
 The technological and analytic methods employed in this study are 
reviewed in Chapter 3. Firstly, the general principles of DNA microarray 
technology are briefly described, taking the Affymetrix GeneChips as an 
example. This is followed by a description of microarray data analysis at 
different levels and for different purposes. The broad spectrum of applications 
of gene expression profiling in oncology is discussed.
 Chapter 4 reports the identification of new diagnostic, classification, 
and prognostic gene signatures for NSCLC. We show that NSCLC tumors can 
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be molecularly distinguished from normal lung tissue by the expression of 
only five genes. The heterogeneity of NSCLC is investigated by comparing 
the expression profiles of the three main subtypes – ADC, SCC, and LCC. The 
dominant properties of these three main histological categories are summarized 
molecularly by the expression of seventy-five genes, including members of the 
keratin- and kinesin families. We also find that the overall survival of NSCLC 
patients, regardless of histological subtypes, can be predicted by the expression 
of seventeen genes. The established association between the gene expression 
profiles described in this study and NSCLC properties is retained when tested 
in an independent NSCLC cohort from Duke University. We propose that these 
newly identified NSCLC expression profiles could be used as biomarkers to 
distinguish NSCLC from non-cancerous cases at early stages, to recognize the 
predominant molecular attributes of individual NSCLC cases, and to predict 
overall survival of the patients.
 In Chapter 5, I report on a study aiming to predict NSCLC sensitivity 
to Pemetrexed therapy using gene expression profiles. A novel subgroup 
of NSCLC is correlated to predicted Pemetrexed resistance based on the 
expression level of TYMS, a major target of Pemetrexed. This novel subgroup 
shows no association with routine histopathology. Distinctive characteristics 
are the presence of neuroendocrine tumor components and a deregulated EGFR 
signaling pathway. We propose that biological characteristics assessed by gene 
expression profiling may aid in reliably stratifying patients with respect to the 
efficacy of Pemetrexed therapy. We also suggest an approach applicable in 
clinical practice that is based on genes whose expression correlates well with that 
of TYMS. Such surrogate markers are potentially useful since it is notoriously 
difficult to assess TYMS expression levels by routine histopathological 
techniques.
 Chapter 6 is a general discussion about the studies carried out in this 
thesis and focuses on current issues that need to be tackled to improve future 
applications of bioinformatics analyses in oncology.
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Longkanker is wereldwijd de meest voorkomende doodsoorzaak ten gevolge 
van kanker. Men denkt dat deze hoge sterftecijfers mede worden veroorzaakt 
doordat vroege detectie van longkanker niet goed mogelijk is met de huidige 
technieken. Een andere belangrijke factor is dat patiënten met gevorderde 
longkanker een zeer variabele response vertonen op dezelfde behandeling. 
Om dit te verbeteren is het belangrijk dat specifieke merkers geïdentificeerd 
worden die de vroege diagnostiek verbeteren. Daarnaast is het wenselijk om 
tumoren te classificeren zodat hun biologisch gedrag voorspeld kan worden. 
De ontwikkeling van accurate modellen om de voortgang van longkanker te 
voorspellen staat nog in de kinderschoenen. Om de kans op slagen van de 
behandeling te verhogen is het nodig om de moleculaire mechanismen die 
resistentie tegen chemotherapie veroorzaken beter te begrijpen.
 In het werk beschreven in dit proefschrift hebben wij een aantal van deze 
onderwerpen benaderd door genexpressieprofielen van tumoren en daarnaast 
gelegen gezond longweefsel te bepalen.
 Hoofdstuk 1 is een algemene inleiding over longkanker. De epidemiologie 
van longkanker, de histologische karakteristieken van de tumoren, klinische 
pathologie, en de huidige prognoses en therapeutische benaderingen passeren 
de revue. Er wordt een overzicht gegeven van de diagnose en classificatie van 
longkanker in de klinische praktijk, de vooruitzichten voor de patiënten, en 
welke mogelijkheden voor behandeling er zijn.
 In Hoofdstuk 2 wordt de diversiteit aan factoren die een bijdrage kunnen 
leveren aan carcinogenese van de long besproken. De verworven afwijkingen 
zorgen ervoor dat het longepitheel van het normale pad van celgroei en 
differentiatie afdwaalt, wat kan leiden tot de initiatie van de transformatie naar 
tumorcellen. Onder de kritische veranderingen die hier beschreven worden 
bevinden zich instabiliteit van chromosoom 3p en 9p, en afwijkende expressie 
van oncogenen (bijvoorbeeld RAS en EGFR) en tumorsuppressorgenen 
(bijvoorbeeld TP53 en RB).
 De technische en analytische methodes die bij onze studies zijn gebruikt 
zijn het onderwerp van Hoofdstuk 3. De algemene principes van DNA micro-
array technologie worden kort beschreven, waarbij de Affymetrix GeneChips 
als voorbeeld worden gebruikt. Dit wordt gevolgd door een beschrijving van de 
analyse van micro-array data, op verschillende niveaus en voor verschillende 
doeleinden. Het brede spectrum van toepassingen van genexpressieprofielen in 
de oncologie wordt belicht.
 In Hoofdstuk 4 beschrijven we de identificatie van nieuwe diagnostische, 
classificatie en prognostische genexpressiesignaturen voor longkanker. We 
laten zien dat de expressie van slechts 5 genen voldoende is om longtumoren 
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moleculair te onderscheiden van normaal longweefsel. De heterogeniteit 
van longkanker werd onderzocht door de genexpressieprofielen van de drie 
belangrijkste subtypes niet-kleincellige longkanker met elkaar te vergelijken. 
De dominante eigenschappen van deze drie belangrijkste histologische 
categorieën kunnen moleculair worden samengevat door de expressieprofielen 
van vijfenzeventig genen, waaronder leden van de keratine- en kinesine 
genfamilies. We vinden ook dat de overlevingstijd van de patiënten voorspeld 
kan worden aan de hand van de expressie van zeventien genen. De associaties 
tussen deze genexpressieprofielen en de eigenschappen van de longtumoren 
hielden stand als ze getest werden op een onafhankelijk cohort longtumoren 
verzameld door de Duke University in de Verenigde Staten. We stellen voor 
dat deze nieuw geïdentificeerde genexpressieprofielen gebruikt kunnen 
worden als biologische merkers om al in vroege stadia longkanker van gezond 
weefsel te onderscheiden, om de dominante histologische kenmerken van 
individuele longtumoren eenduidig vast te stellen, en om de overlevingstijd 
van longkankerpatiënten te voorspellen.
 In Hoofdstuk 5 beschrijf ik een studie gericht op het gebruiken van 
genexpressieprofielen voor het voorspellen van de gevoeligheid van longtumoren 
voor behandeling met Pemetrexed. We identificeren een nieuwe subgroep tumoren 
die volgens de voorspelling resistent zijn tegen Pemetrexed. Dit is gebaseerd 
op de expressie van het enzym thymidylaat synthase (TYMS), een belangrijke 
target van Pemetrexed. Deze nieuwe subgroep kan niet geclassificeerd worden 
met behulp van routine histopathologie. Onderscheidende karakteristieken 
zijn de aanwezigheid van neuro-endocriene componenten, en deregulatie van 
signaaltransductie via de epidermale groeifactor receptor (EGFR). We stellen 
voor dat dergelijke biologische karakteristieken, gereflecteerd in specifieke 
genexpressieprofielen, gebruikt kunnen worden om patiënten die in aanmerking 
komen voor Pemetrexed therapy te selecteren. We doen een suggestie om voor 
de diagnostiek de expressie van genen te gebruiken die nauw gecorreleerd zijn 
met TYMS expressie. Dergelijke surrogaat markers zijn potentieel heel nuttig, 
omdat het vrijwel onmogelijk is om TYMS expressieniveaus betrouwbaar te 
bepalen met routinematige histopathologische technieken.
 Hoofdstuk 6 is een algemene discussie over de studies die beschreven 
worden in dit proefschrift. De meeste aandacht gaat uit naar de huidige 
beperkingen van genoom-brede analyses, en de uitdaging om daar oplossingen 
voor te vinden die in de toekomst toegepast kunnen bij bioinformatica analyses 
in de oncology.
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